1
|
Leonard J, Kepplinger D, Espina V, Gillevet P, Ke Y, Birukov KG, Doctor A, Hoemann CD. Whole blood coagulation in an ex vivo thrombus is sufficient to induce clot neutrophils to adopt a myeloid-derived suppressor cell signature and shed soluble Lox-1. J Thromb Haemost 2024; 22:1031-1045. [PMID: 38135253 DOI: 10.1016/j.jtha.2023.12.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2023] [Revised: 12/04/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023]
Abstract
BACKGROUND Blood clots are living tissues that release inflammatory mediators including IL-8/CXCL8 and MCP-1/CCL2. A deeper understanding of blood clots is needed to develop new therapies for prothrombotic disease states and regenerative medicine. OBJECTIVES To identify a common transcriptional shift in cultured blood clot leukocytes. METHODS Differential gene expression of whole blood and cultured clots (4 hours at 37 °C) was assessed by RNA sequencing (RNAseq), reverse transcriptase-polymerase chain reaction, proteomics, and histology (23 diverse healthy human donors). Cultured clot serum bioactivity was tested in endothelial barrier functional assays. RESULTS All cultured clots developed a polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC) signature, including up-regulation of OLR1 (mRNA encoding lectin-like oxidized low-density lipoprotein receptor 1 [Lox-1]), IL-8/CXCL8, CXCL2, CCL2, IL10, IL1A, SPP1, TREM1, and DUSP4/MKP. Lipopolysaccharide enhanced PMN-MDSC gene expression and specifically induced a type II interferon response with IL-6 production. Lox-1 was specifically expressed by cultured clot CD15+ neutrophils. Cultured clot neutrophils, but not activated platelets, shed copious amounts of soluble Lox-1 (sLox-1) with a donor-dependent amplitude. sLox-1 shedding was enhanced by phorbol ester and suppressed by heparin and by beta-glycerol phosphate, a phosphatase inhibitor. Cultured clot serum significantly enhanced endothelial cell monolayer barrier function, consistent with a proresolving bioactivity. CONCLUSION This study suggests that PMN-MDSC activation is part of the innate immune response to coagulation which may have a protective role in inflammation. The cultured blood clot is an innovative thrombus model that can be used to study both sterile and nonsterile inflammatory states and could be used as a personalized medicine tool for drug screening.
Collapse
Affiliation(s)
- Julia Leonard
- Department of Bioengineering, Institute of Biomedical Engineering, George Mason University, Manassas, Virginia, USA
| | - David Kepplinger
- Department of Statistics, George Mason University, Fairfax, Virginia, USA
| | - Virginia Espina
- Department of Systems Biology, George Mason University, Fairfax, Virginia, USA
| | - Pat Gillevet
- Department of Biology, George Mason University, Fairfax, Virginia, USA
| | - Yunbo Ke
- Department of Anesthesiology, School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland, USA
| | - Konstantin G Birukov
- Department of Anesthesiology, School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland, USA
| | - Allan Doctor
- Departments of Pediatrics & Bioengineering and Center for Blood Oxygen Transport and Hemostasis, School of Medicine, University of Maryland at Baltimore, Baltimore, Maryland, USA
| | - Caroline D Hoemann
- Department of Bioengineering, Institute of Biomedical Engineering, George Mason University, Manassas, Virginia, USA.
| |
Collapse
|
2
|
Leberzammer J, von Hundelshausen P. Chemokines, molecular drivers of thromboinflammation and immunothrombosis. Front Immunol 2023; 14:1276353. [PMID: 37954596 PMCID: PMC10637585 DOI: 10.3389/fimmu.2023.1276353] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2023] [Accepted: 10/12/2023] [Indexed: 11/14/2023] Open
Abstract
Blood clotting is a finely regulated process that is essential for hemostasis. However, when dysregulated or spontaneous, it promotes thrombotic disorders. The fact that these are triggered, accompanied and amplified by inflammation is reflected in the term thromboinflammation that includes chemokines. The role of chemokines in thrombosis is therefore illuminated from a cellular perspective, where endothelial cells, platelets, red blood cells, and leukocytes may be both the source and target of chemokines. Chemokine-dependent prothrombotic processes may thereby occur independently of chemokine receptors or be mediated by chemokine receptors, although the binding and activation of classical G protein-coupled receptors and their signaling pathways differ from those of atypical chemokine receptors, which do not function via cell activation and recruitment. Regardless of binding to their receptors, chemokines can induce thrombosis by forming platelet-activating immune complexes with heparin or other polyanions that are pathognomonic for HIT and VITT. In addition, chemokines can bind to NETs and alter their structure. They also change the electrical charge of the cell surface of platelets and interact with coagulation factors, thereby modulating the balance of fibrinolysis and coagulation. Moreover, CXCL12 activates CXCR4 on platelets independently of classical migratory chemokine activity and causes aggregation and thrombosis via the PI3Kβ and Btk signaling pathways. In contrast, typical chemokine-chemokine receptor interactions are involved in the processes that contribute to the adhesiveness of the endothelium in the initial phase of venous thrombosis, where neutrophils and monocytes subsequently accumulate in massive numbers. Later, the reorganization and resolution of a thrombus require coordinated cell migration and invasion of the thrombus, and, as such, indeed, chemokines recruit leukocytes to existing thrombi. Therefore, chemokines contribute in many independent ways to thrombosis.
Collapse
Affiliation(s)
- Julian Leberzammer
- Institute of Cardiovascular Regeneration, Goethe University Frankfurt, Frankfurt, Germany
- Department of Cardiology and Angiology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
| | - Philipp von Hundelshausen
- German Center for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany
- Institute for Cardiovascular Prevention, Institut für Prophylaxe und Epidemiologie der Kreislaufkrankheiten (IPEK), Ludwig-Maximilians-Universität München, Munich, Germany
| |
Collapse
|
3
|
Chen Z, Li C, Yu J. Monocyte chemoattractant protein-1 as a potential marker for patients with sepsis: a systematic review and meta-analysis. Front Med (Lausanne) 2023; 10:1217784. [PMID: 37720514 PMCID: PMC10502711 DOI: 10.3389/fmed.2023.1217784] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2023] [Accepted: 08/17/2023] [Indexed: 09/19/2023] Open
Abstract
Objective To investigate the diagnostic value of monocyte chemoattractant protein-1 (MCP-1) as a biomarker for adult patients with sepsis. Methods Related studies on the diagnostic value of MCP-1 in adult patients with sepsis were searched in PubMed, Cochrane Library, Embase, CNKI, CBM, Web of Science, Scopus, and Wanfang Data databases (published to February 20, 2023) was performed if studies assessed the diagnostic accuracy of MCP-1 in adult patients with sepsis and provided appropriate information sufficient to construct a 2 × 2 linked table, studies were included. Results Data from 8 studies with a total of 805 patients were included. The combined sensitivity was 0.84 (95% CI 0.70-0.92), the specificity was 0.82 (95% CI 0.67-0.91), the combined positive likelihood ratio was 3.711 (2.119-6.500), the negative likelihood ratio was 0.287 (0.198-0.415), and the area under the working characteristic curve for combined subjects was 0.88. The diagnostic odds ratio (DOR) was 16.508 (7.632-35.706). Meta-regression analysis showed that the results were not significant. Deeks' funnel plot showed that there was no publication bias. Conclusion According to our meta-analysis, MCP-1 is a valuable biomarker and may provide evidence for the diagnosis of sepsis in adults.
Collapse
Affiliation(s)
- Zhuo Chen
- Department of Intensive Care Unit, The Second Hospital of Dalian Medical University, Dalian, China
| | - Chenwei Li
- Department of Pulmonary and Critical Care Medicine, The Second Hospital of Dalian Medical University, Dalian, China
| | - Jian Yu
- Department of Intensive Care Unit, The Second Hospital of Dalian Medical University, Dalian, China
| |
Collapse
|
4
|
Pincez T, Lo KS, D'Orengiani ALPHD, Garrett ME, Brugnara C, Ashley-Koch AE, Telen MJ, Galacteros F, Joly P, Bartolucci P, Lettre G. Variation and impact of polygenic hematologic traits in monogenic sickle cell disease. Haematologica 2023; 108:870-881. [PMID: 36226494 PMCID: PMC9973495 DOI: 10.3324/haematol.2022.281180] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Indexed: 11/09/2022] Open
Abstract
Several of the complications observed in sickle cell disease (SCD) are influenced by variation in hematologic traits (HT), such as fetal hemoglobin (HbF) level and neutrophil count. Previous large-scale genome-wide association studies carried out in largely healthy individuals have identified thousands of variants associated with HT, which have then been used to develop multi-ancestry polygenic trait scores (PTS). Here, we tested whether these PTS associate with HT in SCD patients and if they can improve statistical models associated with SCD-related complications. In 2,056 SCD patients, we found that the PTS predicted less HT variance than in non-SCD individuals of African ancestry. This was particularly striking at the Duffy/DARC locus, where we observed an epistatic interaction between the SCD genotype and the Duffy null variant (rs2814778) that led to a two-fold weaker effect on neutrophil count. PTS for these HT which are measured as part of routine practice were not associated with complications in SCD. In contrast, we found that a simple PTS for HbF that includes only six variants explained a large fraction of the phenotypic variation (20.5-27.1%), associated with acute chest syndrome and stroke risk, and improved the statistical modeling of the vaso-occlusive crisis rate. Using Mendelian randomization, we found that increasing HbF by 4.8% reduces stroke risk by 39% (P=0.0006). Taken together, our results highlight the importance of validating PTS in large diseased populations before proposing their implementation in the context of precision medicine initiatives.
Collapse
Affiliation(s)
- Thomas Pincez
- Montreal Heart Institute, Montreal, Quebec, Canada; Department of Pediatrics, Division of Pediatric Hematology-Oncology, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Universite de Montreal, Montreal, Quebec
| | - Ken Sin Lo
- Montreal Heart Institute, Montreal, Quebec
| | | | - Melanie E Garrett
- Duke Molecular Physiology Institute, Duke University Medical Center, Durham, NC
| | - Carlo Brugnara
- Department of Laboratory Medicine, Boston Children's Hospital, Boston, MA
| | | | - Marilyn J Telen
- Department of Medicine, Division of Hematology, Duke University Medical Center, Durham, NC
| | - Frederic Galacteros
- Red Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil
| | - Philippe Joly
- Unite Fonctionnelle 34445 'Biochimie des Pathologies Erythrocytaires', Laboratoire de Biochimie et Biologie Moleculaire Grand-Est, Groupement Hospitalier Est, Hospices Civils de Lyon, Bron, France; Laboratoire Inter-Universitaire de Biologie de la Motricite (LIBM) EA7424, Equipe 'Biologie Vasculaire et du Globule Rouge', Universite Claude Bernard Lyon 1, Comite d'Universites et d'Etablissements (COMUE), Lyon
| | - Pablo Bartolucci
- Red Cell Genetic Disease Unit, Hopital Henri-Mondor, Assistance Publique-Hopitaux de Paris (AP-HP), Universite Paris Est, IMRB - U955 - Equipe no 2, Creteil
| | - Guillaume Lettre
- Montreal Heart Institute, Montreal, Quebec, Canada; Department of Medicine, Faculty of Medicine, Universite de Montreal, Montreal, Quebec.
| |
Collapse
|
5
|
Park SJ, Kwon S, Lee MS, Jang BH, Guzmán-Cedillo AE, Kang JH. Human Cell-Camouflaged Nanomagnetic Scavengers Restore Immune Homeostasis in a Rodent Model with Bacteremia. SMALL (WEINHEIM AN DER BERGSTRASSE, GERMANY) 2022; 18:e2203746. [PMID: 36070419 DOI: 10.1002/smll.202203746] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2022] [Revised: 07/26/2022] [Indexed: 06/15/2023]
Abstract
Bloodstream infection caused by antimicrobial resistance pathogens is a global concern because it is difficult to treat with conventional therapy. Here, scavenger magnetic nanoparticles enveloped by nanovesicles derived from blood cells (MNVs) are reported, which magnetically eradicate an extreme range of pathogens in an extracorporeal circuit. It is quantitatively revealed that glycophorin A and complement receptor (CR) 1 on red blood cell (RBC)-MNVs predominantly capture human fecal bacteria, carbapenem-resistant (CR) Escherichia coli, and extended-spectrum beta-lactamases-positive (ESBL-positive) E. coli, vancomycin-intermediate Staphylococcus aureus (VISA), endotoxins, and proinflammatory cytokines in human blood. Additionally, CR3 and CR1 on white blood cell-MNVs mainly contribute to depleting the virus envelope proteins of Zika, SARS-CoV-2, and their variants in human blood. Supplementing opsonins into the blood significantly augments the pathogen removal efficiency due to its combinatorial interactions between pathogens and CR1 and CR3 on MNVs. The extracorporeal blood cleansing enables full recovery of lethally infected rodent animals within 7 days by treating them twice in series. It is also validated that parameters reflecting immune homeostasis, such as blood cell counts, cytokine levels, and transcriptomics changes, are restored in blood of the fatally infected rats after treatment.
Collapse
Affiliation(s)
- Sung Jin Park
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), UNIST gil 50, Ulsan, 44919, Republic of Korea
| | - Seyong Kwon
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), UNIST gil 50, Ulsan, 44919, Republic of Korea
| | - Min Seok Lee
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), UNIST gil 50, Ulsan, 44919, Republic of Korea
| | - Bong Hwan Jang
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), UNIST gil 50, Ulsan, 44919, Republic of Korea
| | - Axel E Guzmán-Cedillo
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), UNIST gil 50, Ulsan, 44919, Republic of Korea
| | - Joo H Kang
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology (UNIST), UNIST gil 50, Ulsan, 44919, Republic of Korea
| |
Collapse
|
6
|
Huang Y, Li Q, Hu R, Li R, Yang Y. Five immune-related genes as diagnostic markers for endometriosis and their correlation with immune infiltration. Front Endocrinol (Lausanne) 2022; 13:1011742. [PMID: 36277723 PMCID: PMC9582281 DOI: 10.3389/fendo.2022.1011742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 09/20/2022] [Indexed: 11/13/2022] Open
Abstract
Endometriosis (EMS) is a chronic disease that can cause dysmenorrhea, chronic pelvic pain, and infertility, among other symptoms. EMS diagnosis is often delayed compared to other chronic diseases, and there are currently no accurate, easily accessible, and non-invasive diagnostic tools. Therefore, it is important to elucidate the mechanism of EMS and explore potential biomarkers and diagnostic tools for its accurate diagnosis and treatment. In the present study, we comprehensively analyzed the differential expression, immune infiltration, and interactions of EMS-related genes in three Homo sapiens datasets. Our results identified 332 differentially expressed genes (DEGs) associated with EMS. Gene ontology analysis showed that these changes mainly focused on the positive regulation of endometrial cell proliferation, cell metabolism, and extracellular space, and EMS involved the integrin, complement activation, folic acid metabolism, interleukin, and lipid signaling pathways. The LASSO regression model was established using immune DEGs with an area under the curve of 0.783 for the internal dataset and 0.656 for the external dataset. Five genes with diagnostic value, ACKR1, LMNB1, MFAP4, NMU, and SEMA3C, were screened from M1 and M2 macrophages, activated mast cells, neutrophils, natural killer cells, follicular T helper cells, CD8+, and CD4+ cells. A protein-protein interaction network based on the immune DEGs was constructed, and ten hub genes with the highest scores were identified. Our results may provide a framework for the development of pathological molecular networks in EMS.
Collapse
Affiliation(s)
- Yi Huang
- The First Clinical Medical College, Lanzhou University, Lanzhou, China
| | - Qiong Li
- Department of Obstetrics and Gynecology, Minqin People’s Hospital, Minqin, China
| | - Rui Hu
- The First Clinical Medical College, Lanzhou University, Lanzhou, China
| | - Ruiyun Li
- The First Clinical Medical College, Lanzhou University, Lanzhou, China
| | - Yuan Yang
- The First Clinical Medical College, Lanzhou University, Lanzhou, China
- The Reproductive Medicine Center, The 1st Hospital of Lanzhou University, Lanzhou, China
- *Correspondence: Yuan Yang,
| |
Collapse
|
7
|
Williams PT. Quantile-specific heritability of monocyte chemoattractant protein-1, and relevance to rs1024611-disease interactions. Cytokine 2021; 149:155722. [PMID: 34624603 PMCID: PMC10124179 DOI: 10.1016/j.cyto.2021.155722] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2021] [Revised: 09/20/2021] [Accepted: 09/22/2021] [Indexed: 12/19/2022]
Abstract
BACKGROUND Monocyte chemoattractant protein-1 (MCP-1) concentrations are 34% to 47% heritable. Larger -2518 G/A (rs1024611) genotypes differences are reported for: 1) MCP-1 production in stimulated vs. basal cells; and 2) MCP-1 concentrations in diseased (sepsis, brain abscess, hepatitis B virus, Alzheimer's disease, Behcet's disease, and systemic lupus erythematosus) vs. healthy patients. Those results suggest that the -2518 G/A effect size may depend on whether the phenotype is high or low relative to its distribution (quantile-dependent expressivity). METHOD To test whether quantile-dependent expressivity applies more broadly to genetic influences on MCP-1 concentrations, quantile-specific offspring-parent (βOP) and full-sib regression slopes (βFS) were estimated by applying quantile regression to the age- and sex-adjusted serum MCP-1 concentrations of Framingham Heart Study families. Quantile-specific heritabilities were calculated as h2 = 2βOP/(1 + rspouse) and h2={(1 + 8rspouseβFS)0.5-1}/(2rspouse)). RESULTS Heritability (h2 ± SE) of MCP-1 concentrations increased from 0.15 ± 0.05 at the 10th percentile of the MCP-1 distribution, 0.23 ± 0.04 at the 25th, 0.32 ± 0.05 at the 50th, 0.43 ± 0.07 at the 75th, and 0.44 ± 0.07 at the 90th percentile, or an 0.0041 ± 0.0009 increase for each one-percent increment in the MCP-1 distribution (Plinear trend = 2.4 × 10-5) when estimated from βOP, and (Plinear trend = 7.7 × 10-9) when estimated from βFS. Compared to the 10th percentile, βOP-estimated h2 was 3-fold greater at the 90th percentile (Pdifference = 0.0003), and 6.9-fold greater when estimated from βFS (Pdifference = 3.3 × 10-6). Re-analysis of in vivo comparison of MCP-1 concentrations in controls vs. patients with MCP-1-elevating conditions, and in vitro studies of MCP-1 production in basal vs. stimulated cells, show rs1024611 genotypes differences that were consistent with quantile-dependent expressivity. CONCLUSION The heritability of circulating MCP-1 concentrations is quantile-dependent.
Collapse
Affiliation(s)
- Paul T Williams
- Lawrence Berkeley National Laboratory, Molecular Biophysics & Integrated Bioimaging Division, 1 Cyclotron Road, Berkeley, CA 94720, United States.
| |
Collapse
|
8
|
Haiyambo DH, Aleksenko L, Mumbengegwi D, Bock R, Uusiku P, Malleret B, Rénia L, Quaye IK. Children with Plasmodium vivax infection previously observed in Namibia, were Duffy negative and carried a c.136G > A mutation. BMC Infect Dis 2021; 21:856. [PMID: 34418990 PMCID: PMC8380386 DOI: 10.1186/s12879-021-06573-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Accepted: 08/13/2021] [Indexed: 11/10/2022] Open
Abstract
Background In a previous study, using a molecular approach, we reported the presence of P. vivax in Namibia. Here, we have extended our investigation to the Duffy antigen genetic profile of individuals of the same cohort with and without Plasmodium infections. Methods Participants with P. vivax (n = 3), P. falciparum (n = 23) mono-infections and co-infections of P. vivax/P. falciparum (n = 4), and P. falciparum/P. ovale (n = 3) were selected from seven regions. Participants with similar age but without any Plasmodium infections (n = 47) were also selected from all the regions. Duffy allelic profile was examined using standard PCR followed by sequencing of amplified products. Sequenced samples were also examined for the presence or absence of G125A mutation in codon 42, exon 2. Results All individuals tested carried the − 67 T > C mutation. However, while all P. vivax infected participants carried the c.G125A mutation, 7/28 P. falciparum infected participants and 9/41 of uninfected participants did not have the c.G125A mutation. The exon 2 region surrounding codon 42, had a c.136G > A mutation that was present in all P. vivax infections. The odds ratio for lack of this mutation with P. vivax infections was (OR 0.015, 95% CI 0.001–0.176; p = 0.001). Conclusion We conclude that P. vivax infections previously reported in Namibia, occurred in Duffy negative participants, carrying the G125A mutation in codon 42. The role of the additional mutation c.136 G > A in exon 2 in P. vivax infections, will require further investigations.
Collapse
Affiliation(s)
- Daniel Hosea Haiyambo
- Department of Biochemistry and Microbiology, University of Namibia School of Medicine, Windhoek, Namibia
| | - Larysa Aleksenko
- Department of Clinical Sciences, University of Lund, Lund, Sweden
| | - Davies Mumbengegwi
- Multidisciplinary Research Center, University of Namibia, Windhoek, Namibia
| | - Ronnie Bock
- Department of Biology, University of Namibia, Windhoek, Namibia
| | - Petrina Uusiku
- Ministry of Health and Social Services Department of Biology, National Vector Borne Disease Control Program, Windhoek, Namibia
| | - Benoit Malleret
- Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.,Immunology Programme, Life Sciences Institute, National University of Singapore, Singapore, Singapore.,Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore
| | - Laurent Rénia
- A*STAR ID Labs, Agency for Science, Technology and Research (A*STAR), Biopolis, Singapore.,Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, Singapore, 308232, Singapore
| | - Isaac Kweku Quaye
- Faculty of Engineering, Computer and Applied Sciences, Regent University College of Science and Technology, Dansoman, P. O. Box DS 1636, Accra, Ghana.
| |
Collapse
|
9
|
Böhm EW, Pavlaki M, Chalikias G, Mikroulis D, Georgiadis GS, Tziakas DN, Konstantinides S, Schäfer K. Colocalization of Erythrocytes and Vascular Calcification in Human Atherosclerosis: A Systematic Histomorphometric Analysis. TH OPEN 2021; 5:e113-e124. [PMID: 33870075 PMCID: PMC8046517 DOI: 10.1055/s-0041-1725042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2020] [Accepted: 01/18/2021] [Indexed: 11/03/2022] Open
Abstract
Background Intimal calcification typically develops in advanced atherosclerosis, and microcalcification may promote plaque progression and instability. Conversely, intraplaque hemorrhage and erythrocyte extravasation may stimulate osteoblastic differentiation and intralesional calcium phosphate deposition. The presence of erythrocytes and their main cellular components (membranes, hemoglobin, and iron) and colocalization with calcification has never been systematically studied. Methods and Results We examined three types of diseased vascular tissue specimens, namely, degenerative aortic valve stenosis ( n = 46), atherosclerotic carotid artery plaques ( n = 9), and abdominal aortic aneurysms ( n = 14). Biomaterial was obtained from symptomatic patients undergoing elective aortic valve replacement, carotid artery endatherectomy, or aortic aneurysm repair, respectively. Serial sections were stained using Masson-Goldner trichrome, Alizarin red S, and Perl's iron stain to visualize erythrocytes, extracelluar matrix and osteoid, calcium phosphate deposition, or the presence of iron and hemosiderin, respectively. Immunohistochemistry was employed to detect erythrocyte membranes (CD235a), hemoglobin or the hemoglobin scavenger receptor (CD163), endothelial cells (CD31), myofibroblasts (SMA), mesenchymal cells (osteopontin), or osteoblasts (periostin). Our analyses revealed a varying degree of intraplaque hemorrhage and that the majority of extravasated erythrocytes were lysed. Osteoid and calcifications also were frequently present, and erythrocyte membranes were significantly more prevalent in areas with calcification. Areas with extravasated erythrocytes frequently contained CD163-positive cells, although calcification also occurred in areas without CD163 immunosignals. Conclusion Our findings underline the presence of extravasated erythrocytes and their membranes in different types of vascular lesions, and their association with areas of calcification suggests an active role of erythrocytes in vascular disease processes.
Collapse
Affiliation(s)
- Elsa Wilma Böhm
- Department of Cardiology, University Medical Center, Mainz, Germany
| | - Maria Pavlaki
- Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece
| | - Georgios Chalikias
- Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece
| | - Dimitrios Mikroulis
- Department of Cardiothoracic Surgery, Democritus University of Thrace, Alexandroupolis, Greece
| | - George S Georgiadis
- Department of Vascular Surgery, Democritus University of Thrace, Alexandroupolis, Greece
| | - Dimitrios N Tziakas
- Department of Cardiology, Democritus University of Thrace, Alexandroupolis, Greece
| | | | - Katrin Schäfer
- Department of Cardiology, University Medical Center, Mainz, Germany
| |
Collapse
|
10
|
Ueberroth BE, Khan A, Zhang KJ, Philip PA. Differences in Baseline Characteristics and White Blood Cell Ratios Between Racial Groups in Patients with Pancreatic Adenocarcinoma. J Gastrointest Cancer 2021; 52:160-168. [PMID: 32077005 DOI: 10.1007/s12029-020-00378-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
PURPOSE Pancreatic adenocarcinoma remains a malignancy with poor prognosis. Black patients experience poorer overall survival compared with other races. Recent studies have elucidated certain prognostic factors at the time of diagnosis of pancreatic cancer which have largely not been studied for differences between racial groups. We present a study examining differences in blood levels between Black and non-Black patients and their effects on overall survival. METHODS This is a retrospective cohort study. One hundred sixty-three patients were confirmed to carry a tissue diagnosis of pancreatic adenocarcinoma and included in analysis; 27 of the patients were self-identified as "Black"; 136 were analyzed together as "Non-Black" with the majority identifying as "White". Various blood markers were drawn at the time of diagnosis. Kaplan-Meier and multivariable Cox regression models were used to examine differences in these factors between Black and non-Black patients, as well as their effect on overall survival. RESULTS Black patients were younger at diagnosis (p = 0.001) and were more likely to experience significant weight loss leading up to diagnosis (p = 0.009); Black patients also had a lower neutrophil-to-lymphocyte ratio (NLR) (p = 0.001) and higher lymphocyte-to-monocyte ratio (LMR) (p = 0.001) at diagnosis. In multivariable analysis, an NLR > 3.5 had a significantly negative impact on overall survival (p = 0.002), as did the presence of metastatic disease (p < 0.001). CONCLUSION Black patients demonstrated a "favorable" white blood cell profile (higher LMR, lower NLR) compared with non-Black patients. This may suggest that the immune response in pancreatic adenocarcinoma is not what is driving disparately poor outcomes in Black patients. Further study is warranted to ascertain the role of immune response in pancreatic adenocarcinoma, the prognostic use of these measurements at diagnosis, and possible other factors, such as genetics, which may better explain poorer outcomes in Black patients.
Collapse
Affiliation(s)
- Benjamin E Ueberroth
- Wayne State University School of Medicine, 540 E Canfield St, Detroit, MI, 48201, USA.
- Department of Internal Medicine, Mayo Clinic, 13400 E Shea Blvd, Scottsdale, AZ, 85259, USA.
| | - Adnan Khan
- Wayne State University School of Medicine, 540 E Canfield St, Detroit, MI, 48201, USA
- Department of Internal Medicine, Kaiser Permanente, 3801 Howe St, Oakland, CA, 94611, USA
| | - Kevin J Zhang
- Wayne State University School of Medicine, 540 E Canfield St, Detroit, MI, 48201, USA
- Department of Internal Medicine, Indiana University, 1120 W Michigan St, Indianapolis, IN, 46202, USA
| | - Philip A Philip
- Wayne State University School of Medicine, 540 E Canfield St, Detroit, MI, 48201, USA
- Barbara Ann Karmanos Cancer Institute, 4100 John R St, Detroit, MI, 48201, USA
| |
Collapse
|
11
|
Kalaoja M, Corbin LJ, Tan VY, Ahola‐Olli AV, Havulinna AS, Santalahti K, Pitkänen N, Lehtimäki T, Lyytikäinen L, Raitoharju E, Seppälä I, Kähönen M, Ripatti S, Palotie A, Perola M, Viikari JS, Jalkanen S, Maksimow M, Salomaa V, Salmi M, Raitakari OT, Kettunen J, Timpson NJ. The Role of Inflammatory Cytokines as Intermediates in the Pathway from Increased Adiposity to Disease. Obesity (Silver Spring) 2021; 29:428-437. [PMID: 33491305 PMCID: PMC8614117 DOI: 10.1002/oby.23060] [Citation(s) in RCA: 24] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/22/2020] [Revised: 09/18/2020] [Accepted: 09/21/2020] [Indexed: 12/28/2022]
Abstract
OBJECTIVE This study aimed to investigate the role of cytokines as intermediates in the pathway from increased adiposity to disease. METHODS BMI and circulating levels of up to 41 cytokines were measured in individuals from three Finnish cohort studies (n = 8,293). Mendelian randomization (MR) was used to assess the impact of BMI on circulating cytokines and the impact of BMI-driven cytokines on risk of obesity-related diseases. RESULTS Observationally, BMI was associated with 19 cytokines. For every SD increase in BMI, causal effect estimates were strongest for hepatocyte growth factor, monocyte chemotactic protein-1 (MCP-1), and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and were as ratios of geometric means 1.13 (95% CI: 1.08-1.19), 1.08 (95% CI: 1.04-1.14), and 1.13 (95% CI: 1.04-1.21), respectively. TRAIL was associated with a small increase in the odds of coronary artery disease (odds ratio: 1.03; 95% CI: 1.00-1.06). There was inconsistent evidence for a protective role of MCP-1 against inflammatory bowel diseases. CONCLUSIONS Observational and MR estimates of the effect of BMI on cytokine levels were generally concordant. There was little evidence for an effect of raised levels of BMI-driven cytokines on disease. These findings illustrate the challenges of MR when applied in the context of molecular mediation.
Collapse
|
12
|
Restivo I, Attanzio A, Tesoriere L, Allegra M. Suicidal Erythrocyte Death in Metabolic Syndrome. Antioxidants (Basel) 2021; 10:antiox10020154. [PMID: 33494379 PMCID: PMC7911029 DOI: 10.3390/antiox10020154] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2020] [Revised: 01/15/2021] [Accepted: 01/18/2021] [Indexed: 02/07/2023] Open
Abstract
Eryptosis is a coordinated, programmed cell death culminating with the disposal of cells without disruption of the cell membrane and the release of endocellular oxidative and pro-inflammatory milieu. While providing a convenient form of death for erythrocytes, dysregulated eryptosis may result in a series of detrimental and harmful pathological consequences highly related to the endothelial dysfunction (ED). Metabolic syndrome (MetS) is described as a cluster of cardiometabolic factors (hyperglycemia, dyslipidemia, hypertension and obesity) that increases the risk of cardiovascular complications such as those related to diabetes and atherosclerosis. In the light of the crucial role exerted by the eryptotic process in the ED, the focus of the present review is to report and discuss the involvement of eryptosis within MetS, where vascular complications are utterly relevant. Current knowledge on the mechanisms leading to eryptosis in MetS-related conditions (hyperglycemia, dyslipidemia, hypertension and obesity) will be analyzed. Moreover, clinical evidence supporting or proposing a role for eryptosis in the ED, associated to MetS cardiovascular complications, will be discussed.
Collapse
Affiliation(s)
| | | | - Luisa Tesoriere
- Correspondence: (L.T.); (M.A.); Tel.: +39-091-238-96803 (L.T. & M.A.)
| | - Mario Allegra
- Correspondence: (L.T.); (M.A.); Tel.: +39-091-238-96803 (L.T. & M.A.)
| |
Collapse
|
13
|
Hillary RF, Trejo-Banos D, Kousathanas A, McCartney DL, Harris SE, Stevenson AJ, Patxot M, Ojavee SE, Zhang Q, Liewald DC, Ritchie CW, Evans KL, Tucker-Drob EM, Wray NR, McRae AF, Visscher PM, Deary IJ, Robinson MR, Marioni RE. Multi-method genome- and epigenome-wide studies of inflammatory protein levels in healthy older adults. Genome Med 2020; 12:60. [PMID: 32641083 PMCID: PMC7346642 DOI: 10.1186/s13073-020-00754-1] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2020] [Accepted: 06/10/2020] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The molecular factors which control circulating levels of inflammatory proteins are not well understood. Furthermore, association studies between molecular probes and human traits are often performed by linear model-based methods which may fail to account for complex structure and interrelationships within molecular datasets. METHODS In this study, we perform genome- and epigenome-wide association studies (GWAS/EWAS) on the levels of 70 plasma-derived inflammatory protein biomarkers in healthy older adults (Lothian Birth Cohort 1936; n = 876; Olink® inflammation panel). We employ a Bayesian framework (BayesR+) which can account for issues pertaining to data structure and unknown confounding variables (with sensitivity analyses using ordinary least squares- (OLS) and mixed model-based approaches). RESULTS We identified 13 SNPs associated with 13 proteins (n = 1 SNP each) concordant across OLS and Bayesian methods. We identified 3 CpG sites spread across 3 proteins (n = 1 CpG each) that were concordant across OLS, mixed-model and Bayesian analyses. Tagged genetic variants accounted for up to 45% of variance in protein levels (for MCP2, 36% of variance alone attributable to 1 polymorphism). Methylation data accounted for up to 46% of variation in protein levels (for CXCL10). Up to 66% of variation in protein levels (for VEGFA) was explained using genetic and epigenetic data combined. We demonstrated putative causal relationships between CD6 and IL18R1 with inflammatory bowel disease and between IL12B and Crohn's disease. CONCLUSIONS Our data may aid understanding of the molecular regulation of the circulating inflammatory proteome as well as causal relationships between inflammatory mediators and disease.
Collapse
Affiliation(s)
- Robert F Hillary
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
| | - Daniel Trejo-Banos
- Department of Computational Biology, University of Lausanne, 1015, Lausanne, Switzerland
| | - Athanasios Kousathanas
- Department of Computational Biology, University of Lausanne, 1015, Lausanne, Switzerland
| | - Daniel L McCartney
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
| | - Sarah E Harris
- Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
- Lothian Birth Cohorts, University of Edinburgh, Edinburgh, EH8 9JZ, UK
| | - Anna J Stevenson
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
| | - Marion Patxot
- Department of Computational Biology, University of Lausanne, 1015, Lausanne, Switzerland
| | - Sven Erik Ojavee
- Department of Computational Biology, University of Lausanne, 1015, Lausanne, Switzerland
| | - Qian Zhang
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072, Australia
| | - David C Liewald
- Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
| | - Craig W Ritchie
- Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, EH16 4UX, UK
| | - Kathryn L Evans
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK
| | - Elliot M Tucker-Drob
- Department of Psychology, The University of Texas at Austin, Austin, TX, 78712, USA
- Population Research Center, The University of Texas at Austin, Austin, TX, 78712, USA
| | - Naomi R Wray
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072, Australia
| | - Allan F McRae
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072, Australia
| | - Peter M Visscher
- Institute for Molecular Bioscience, University of Queensland, Brisbane, Queensland, 4072, Australia
| | - Ian J Deary
- Department of Psychology, University of Edinburgh, Edinburgh, EH8 9JZ, UK
- Lothian Birth Cohorts, University of Edinburgh, Edinburgh, EH8 9JZ, UK
| | - Matthew R Robinson
- Institute of Science and Technology Austria, 3400, Klosterneuburg, Austria.
| | - Riccardo E Marioni
- Centre for Genomic and Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK.
| |
Collapse
|
14
|
Do Blood Group Antigens and the Red Cell Membrane Influence Human Immunodeficiency Virus Infection? Cells 2020; 9:cells9040845. [PMID: 32244465 PMCID: PMC7226767 DOI: 10.3390/cells9040845] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2020] [Revised: 03/15/2020] [Accepted: 03/26/2020] [Indexed: 12/18/2022] Open
Abstract
The expression of blood group antigens varies across human populations and geographical regions due to natural selection and the influence of environment factors and disease. The red cell membrane is host to numerous surface antigens which are able to influence susceptibility to disease, by acting as receptors for pathogens, or by influencing the immune response. Investigations have shown that Human Immunodeficiency Virus (HIV) can bind and gain entry into erythrocytes, and therefore it is hypothesized that blood groups could play a role in this process. The ABO blood group has been well studied. However, its role in HIV susceptibility remains controversial, while other blood group antigens, and the secretor status of individuals, have been implicated. The Duffy antigen is a chemokine receptor that is important in the inflammatory response. Those who lack this antigen, and type as Duffy null, could therefore be susceptible to HIV infection, especially if associated with neutropenia. Other antigens including those in the Rh, Lutheran and OK blood group systems have all been shown to interact with HIV. More recently, experiments show that cells which overexpress the Pk antigen appear to be protected against infection. These reports all demonstrate that red cell antigens interact and influence HIV infection. However, as the red cell membrane is complex and the pathogenesis of HIV multi-factorial, the role of blood group antigens cannot be studied in isolation.
Collapse
|
15
|
Sjöberg E, Meyrath M, Chevigné A, Östman A, Augsten M, Szpakowska M. The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy. Adv Cancer Res 2020; 145:99-138. [PMID: 32089166 DOI: 10.1016/bs.acr.2019.12.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Chemokines regulate directed cell migration, proliferation and survival and are key components in cancer biology. They exert their functions by interacting with seven-transmembrane domain receptors that signal through G proteins (GPCRs). A subgroup of four chemokine receptors known as the atypical chemokine receptors (ACKRs) has emerged as essential regulators of the chemokine functions. ACKRs play diverse and complex roles in tumor biology from tumor initiation to metastasis, including cancer cell proliferation, adherence to endothelium, epithelial-mesenchymal transition (EMT), extravasation from blood vessels, tumor-associated angiogenesis or protection from immunological responses. This chapter gives an overview on the established and emerging roles that the atypical chemokine receptors ACKR1, ACKR2, ACKR3 and ACKR4 play in the different phases of cancer development and dissemination, their clinical relevance, as well as on the hurdles to overcome in ACKRs targeting as cancer therapy.
Collapse
Affiliation(s)
- Elin Sjöberg
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | - Max Meyrath
- Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg
| | - Andy Chevigné
- Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg
| | - Arne Östman
- Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden
| | | | - Martyna Szpakowska
- Department of Infection and Immunity, Immuno-Pharmacology and Interactomics, Luxembourg Institute of Health (LIH), Esch-sur-Alzette, Luxembourg.
| |
Collapse
|
16
|
Eckert N, Werth K, Willenzon S, Tan L, Förster R. B cell hyperactivation in an Ackr4-deficient mouse strain is not caused by lack of ACKR4 expression. J Leukoc Biol 2019; 107:1155-1166. [PMID: 31841228 DOI: 10.1002/jlb.2ma1119-300r] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2019] [Revised: 11/27/2019] [Accepted: 11/29/2019] [Indexed: 12/14/2022] Open
Abstract
The majority of genetically modified C57BL/6 mice contain congenic passenger DNA around the targeted gene locus as they were generated from 129-derived embryonic stem cells (ESCs) with subsequent backcrossing to the C57BL/6 genetic background. When studying the role of atypical chemokine receptor 4 (ACKR4) in the immune system, we realized that the two available Ackr4-deficient mouse strains (Ackr4-/- and Ackr4GFP/GFP ) show profoundly different phenotypes: Compared to wild-type and Ackr4GFP/GFP mice, Ackr4-/- mice show a strong accumulation of plasma blasts in mesenteric lymph node and spleen as well as increased B cell proliferation after in vitro activation. This phenotype was maintained after further backcrossing to C57BL/6 mice and was even present in heterozygous Ackr4+/- animals, suggesting that a gene variant on the targeted chromosome might cause this phenotype. Exome sequencing revealed that a region of approximately 20 Mbp around the Ackr4 locus on chromosome 9 still originates from the 129 background based on high variant density observed. In activated Ackr4-/- and Ackr4GFP/GFP B cells, transcripts of genes around the Ackr4 locus were equally deregulated compared to C57BL/6 B cells, whereas increased expression of IL-6 was selectively observed in B cells of Ackr4-/- mice. Because the gene encoding for IL-6 is placed on chromosome 5 these findings suggest that passenger DNA around the Ackr4 locus has an indirect effect on B cell activation and IL-6 production. Results of the present study should not only lead to the reinterpretation of data from earlier studies using Ackr4-/- mice but should remind the scientific community about the limitations of mouse models using mice created by gene-targeting of nonsyngeneic ESCs.
Collapse
Affiliation(s)
- Nadine Eckert
- Institute of Immunology, Hannover Medical School, Carl-Neuberg-Straße, Hannover, Germany
| | - Kathrin Werth
- Institute of Immunology, Hannover Medical School, Carl-Neuberg-Straße, Hannover, Germany
| | - Stefanie Willenzon
- Institute of Immunology, Hannover Medical School, Carl-Neuberg-Straße, Hannover, Germany
| | - Likai Tan
- Institute of Immunology, Hannover Medical School, Carl-Neuberg-Straße, Hannover, Germany
| | - Reinhold Förster
- Institute of Immunology, Hannover Medical School, Carl-Neuberg-Straße, Hannover, Germany.,Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Carl-Neuberg-Straße, Hannover, Germany
| |
Collapse
|
17
|
The emerging role of red blood cells in cytokine signalling and modulating immune cells. Blood Rev 2019; 41:100644. [PMID: 31812320 DOI: 10.1016/j.blre.2019.100644] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Revised: 11/13/2019] [Accepted: 11/22/2019] [Indexed: 02/07/2023]
Abstract
For many years red blood cells have been described as inert bystanders rather than participants in intercellular signalling, immune function, and inflammatory processes. However, studies are now reporting that red blood cells from healthy individuals regulate immune cell activity and maturation, and red blood cells from disease cohorts are dysfunctional. These cells have now been shown to bind more than 50 cytokines and have been described as a sink for these molecules, and the loss of this activity has been correlated with disease progression. In this review, we summarise what is currently understood about the role of red blood cells in cytokine signalling and in modulating the activity of immune cells. We also discuss the implications of these findings for transfusion medicine and in furthering our understanding of anaemia of chronic inflammation. By bringing these disparate units of work together, we aim to shine a light on an area that requires significantly more investigation.
Collapse
|
18
|
Chemokine (C-C motif) ligand 2 and coronary artery disease: Tissue expression of functional and atypical receptors. Cytokine 2019; 126:154923. [PMID: 31739217 DOI: 10.1016/j.cyto.2019.154923] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2019] [Revised: 11/06/2019] [Accepted: 11/08/2019] [Indexed: 12/12/2022]
Abstract
Chemokines, particularly chemokine (C-C- motif) ligand 2 (CCL2), control leukocyte migration into the wall of the artery and regulate the traffic of inflammatory cells. CCL2 is bound to functional receptors (CCR2), but also to atypical chemokine receptors (ACKRs), which do not induce cell migration but can modify chemokine gradients. Whether atherosclerosis alters CCL2 function by influencing the expression of these receptors remains unknown. In a necropsy study, we used immunohistochemistry to explore where and to what extent CCL2 and related receptors are present in diseased arteries that caused the death of men with coronary artery disease compared with unaffected arteries. CCL2 was marginally detected in normal arteries but was more frequently found in the intima. The expression of CCL2 and related receptors was significantly increased in diseased arteries with relative differences among the artery layers. The highest relative increases were those of CCL2 and ACKR1. CCL2 expression was associated with a significant predictive value of atherosclerosis. Findings suggest the need for further insight into receptor specificity or activity and the interplay among chemokines. CCL2-associated conventional and atypical receptors are overexpressed in atherosclerotic arteries, and these may suggest new potential therapeutic targets to locally modify the overall anti-inflammatory response.
Collapse
|
19
|
Jiménez-Sousa MÁ, Gómez-Moreno AZ, Pineda-Tenor D, Sánchez-Ruano JJ, Artaza-Varasa T, Martin-Vicente M, Fernández-Rodríguez A, Martínez I, Resino S. Impact of DARC rs12075 Variants on Liver Fibrosis Progression in Patients with Chronic Hepatitis C: A Retrospective Study. Biomolecules 2019; 9:E143. [PMID: 30970632 PMCID: PMC6523653 DOI: 10.3390/biom9040143] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2019] [Revised: 04/05/2019] [Accepted: 04/07/2019] [Indexed: 02/07/2023] Open
Abstract
: The Duffy antigen receptor for chemokines (DARC) rs12075 polymorphism regulates leukocyte trafficking and proinflammatory chemokine homeostasis. Hepatitis C virus (HCV)-mediated liver fibrosis is associated with an uncontrolled inflammatory response. In this study, we evaluate the association between the DARC rs12075 polymorphism and liver stiffness progression in HCV-infected patients. We carried out a retrospective cohort study (repeated measures design) in 208 noncirrhotic patients with chronic hepatitis C (CHC) who had at least two liver stiffness measurements (LSM) with a separation of at least 12 months. We used generalized linear models to analyze the association between DARC rs12075 polymorphism and outcome variables. During a follow-up of 46.6 months, the percentage of patients with stages of fibrosis F0/F1 decreased (p < 0.001), while LSM values and the percentage of patients with cirrhosis increased (p < 0.001). This pattern of changes was maintained in each of the groups of patients analyzed according to their rs12075 genotypes (AA or AG/GG). However, the variations in liver stiffness characteristics were lower in patients with the rs12075 AG/GG genotype (AG/GG versus AA). Thereby, in the adjusted analysis, patients with the rs12075 AG/GG genotype had a lower risk of an increased value of LSM2/LSM1 arithmetic mean ratio (AMR = 0.83; p = 0.001) and of an increase in LSM ≥ 5 kPa (odds ratio (OR) = 0.28; p = 0.009). Besides, patients with rs12075 AG/GG had a lower risk of cirrhosis progression (OR = 0.24; p = 0.009). No significant associations were found for an increase in LSM ≥ 10 kPa. We found an association between the DARC rs12075 single nucleotide polymorphism (SNP) and CHC progression. Specifically, patients with the DARC rs12075 AG/GG genotype had a lower risk of liver fibrosis progression and development of cirrhosis.
Collapse
Affiliation(s)
- María Ángeles Jiménez-Sousa
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
| | | | - Daniel Pineda-Tenor
- Servicio de Laboratorio Clínico, Hospital de Antequera, 29200 Málaga, Spain.
| | | | | | - María Martin-Vicente
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
| | - Amanda Fernández-Rodríguez
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
| | - Isidoro Martínez
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
| | - Salvador Resino
- Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, 28220 Majadahonda, Spain.
| |
Collapse
|
20
|
Rappoport N, Simon AJ, Amariglio N, Rechavi G. The Duffy antigen receptor for chemokines, ACKR1,- 'Jeanne DARC' of benign neutropenia. Br J Haematol 2018; 184:497-507. [PMID: 30592023 DOI: 10.1111/bjh.15730] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Benign neutropenia, observed in different ethnic groups, is the most common form of neutropenia worldwide. A specific single nucleotide polymorphism, rs2814778, located at the promoter of the ACKR1 (previously termed DARC) gene, which disrupts a binding site for the GATA1 erythroid transcription factor, resulting in a ACKR1-null phenotype, was found to serve as a predictor of low white blood cell and neutrophil counts in African-Americans and Yemenite Jews. Individuals with benign neutropenia due to the ACKR1-null allele have been found to have an increased susceptibility to human immunodeficiency virus infection and, on the other hand, a protective effect against malaria. The associated protective effect may explain the spread of the ACKR1-null allele by natural selection. The reviewed relationships between ACKR1 polymorphism and various pathological states may have important clinical implications to individuals with and without benign neutropenia. Potential mechanisms for ACKR1 (previously termed DARC) modulation during neutrophil recruitment to inflammation, and chemokine bioavailability in the circulation and in local tissue are reviewed and discussed.
Collapse
Affiliation(s)
- Naama Rappoport
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Amos J Simon
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Institute of Haematology, Sheba Medical Centre, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Ninette Amariglio
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Institute of Haematology, Sheba Medical Centre, Tel Hashomer, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.,Mina and Everard Goodman Faculty of Life Sciences, Bar Ilan University, Ramat-Gan, Israel
| | - Gideon Rechavi
- Cancer Research Centre, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
21
|
Lima-Oliveira G, Monneret D, Guerber F, Guidi GC. Sample management for clinical biochemistry assays: Are serum and plasma interchangeable specimens? Crit Rev Clin Lab Sci 2018; 55:480-500. [PMID: 30309270 DOI: 10.1080/10408363.2018.1499708] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
The constrained economic context leads laboratories to centralize their routine analyses on high-throughput platforms, to which blood collection tubes are sent from peripheral sampling sites that are sometimes distantly located. Providing biochemistry results as quickly as possible implies to consolidate the maximum number of tests on a minimum number of blood collection tubes, mainly serum tubes and/or tubes with anticoagulants. However, depending on the parameters and their pre-analytical conditions, the type of matrix - serum or plasma - may have a significant impact on results, which is often unknown or underestimated in clinical practice. Importantly, the matrix-related effects may be a limit to the consolidation of analyses on a single tube, and thus must be known by laboratory professionals. The purpose of the present critical review is to put forward the main differences between using serum and plasma samples on clinical biochemistry analyses, in order to sensitize laboratory managers to the need for standardization. To enrich the debate, we also provide an additional comparison of serum and plasma concentrations for approximately 30 biochemistry parameters. Properties, advantages, and disadvantages of serum and plasma are discussed from a pre-analytical standpoint - before, during, and after centrifugation - with an emphasis on the importance of temperature, delay, and transport conditions. Then, differences in results between these matrices are addressed for many classes of biochemistry markers, particularly proteins, enzymes, electrolytes, lipids, circulating nucleic acids, metabolomics markers, and therapeutic drugs. Finally, important key-points are proposed to help others choose the best sample matrix and guarantee quality of clinical biochemistry assays. Moreover, awareness of the implications of using serum and plasma samples on various parameters assayed in the laboratory is an important requirement to ensure reliable results and improve patient care.
Collapse
Affiliation(s)
- Gabriel Lima-Oliveira
- a Section of Clinical Biochemistry, Department of Neurosciences , Biomedicine and Movement Sciences, University of Verona , Verona , Italy.,b Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI) , Montevideo , Uruguay
| | - Denis Monneret
- c Department of Biochemistry and Molecular Biology , Lyon Sud Hospital Group, Hospices Civils de Lyon , Pierre Bénite , France
| | | | - Gian Cesare Guidi
- a Section of Clinical Biochemistry, Department of Neurosciences , Biomedicine and Movement Sciences, University of Verona , Verona , Italy.,b Latin American Working Group for Preanalytical Phase (WG-PRE-LATAM) of the Latin America Confederation of Clinical Biochemistry (COLABIOCLI) , Montevideo , Uruguay
| |
Collapse
|
22
|
Benson TW, Weintraub DS, Crowe M, Yiew NKH, Popoola O, Pillai A, Joseph J, Archer K, Greenway C, Chatterjee TK, Mintz J, Stepp DW, Stansfield BK, Chen W, Brittain J, Bogdanov VY, Gao Y, Wilson JG, Tang Y, Kim HW, Weintraub NL. Deletion of the Duffy antigen receptor for chemokines (DARC) promotes insulin resistance and adipose tissue inflammation during high fat feeding. Mol Cell Endocrinol 2018; 473:79-88. [PMID: 29341885 PMCID: PMC6045443 DOI: 10.1016/j.mce.2018.01.006] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/21/2017] [Revised: 01/11/2018] [Accepted: 01/12/2018] [Indexed: 12/14/2022]
Abstract
OBJECTIVE Inflammation in adipose tissues in obesity promotes insulin resistance and metabolic disease. The Duffy antigen receptor for chemokines (DARC) is a promiscuous non-signaling receptor expressed on erythrocytes and other cell types that modulates tissue inflammation by binding chemokines such as monocyte chemoattractant protein-1 (MCP-1) and by acting as a chemokine reservoir. DARC allelic variants are common in humans, but the role of DARC in modulating obesity-related metabolic disease is unknown. METHODS We examined body weight gain, tissue adiposity, metabolic parameters and inflammatory marker expression in wild-type and DARC knockout mice fed a chow diet (CD) and high fat diet (HFD). RESULTS Compared to wild-type mice, HFD-fed DARC knockout mice developed glucose intolerance and insulin resistance independent of increases in body weight or adiposity. Interestingly, insulin sensitivity was also diminished in lean male DARC knockout mice fed a chow diet. Insulin production was not reduced by DARC gene deletion, and plasma leptin levels were similar in HFD fed wild-type and DARC knockout mice. MCP-1 levels in plasma rose significantly in the HFD fed wild-type mice, but not in the DARC knockout mice. Conversely, adipose tissue MCP-1 levels were higher, and more macrophage crown-like structures were detected, in the HFD fed DARC knockout mice as compared with the wild-type mice, consistent with augmented adipose tissue inflammation that is not accurately reflected by plasma levels of DARC-bound MCP-1 in these mice. CONCLUSIONS These findings suggest that DARC regulates metabolic function and adipose tissue inflammation, which may impact obesity-related disease in ethnic populations with high frequencies of DARC allelic variants.
Collapse
Affiliation(s)
- Tyler W Benson
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Daniel S Weintraub
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Matthew Crowe
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Nicole K H Yiew
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Departments of Pharmacology and Toxicology, Medical College of Georgia at Augusta University, United States
| | - Orishebawo Popoola
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Ajay Pillai
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Joel Joseph
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Krystal Archer
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Charlotte Greenway
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - Tapan K Chatterjee
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - James Mintz
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States
| | - David W Stepp
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Physiology, Medical College of Georgia at Augusta University, United States
| | - Brian K Stansfield
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Pediatrics, Medical College of Georgia at Augusta University, United States
| | - Weiqin Chen
- Physiology, Medical College of Georgia at Augusta University, United States
| | - Julia Brittain
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Cellular Biology and Anatomy, Medical College of Georgia at Augusta University, United States
| | - Vladimir Y Bogdanov
- Department of Medicine, University of Cincinnati College of Medicine, United States
| | - Yan Gao
- Department of Physiology and Biophysics, University of Mississippi Medical Center, United States
| | - James G Wilson
- Department of Physiology and Biophysics, University of Mississippi Medical Center, United States
| | - Yaoliang Tang
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Medicine, Medical College of Georgia at Augusta University, United States
| | - Ha Won Kim
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Medicine, Medical College of Georgia at Augusta University, United States.
| | - Neal L Weintraub
- Vascular Biology Center, Medical College of Georgia at Augusta University, United States; Medicine, Medical College of Georgia at Augusta University, United States.
| |
Collapse
|
23
|
Omori K, Katakami N, Yamamoto Y, Ninomiya H, Takahara M, Matsuoka TA, Bamba T, Fukusaki E, Shimomura I. Identification of Metabolites Associated with Onset of CAD in Diabetic Patients Using CE-MS Analysis: A Pilot Study. J Atheroscler Thromb 2018; 26:233-245. [PMID: 30068816 PMCID: PMC6402886 DOI: 10.5551/jat.42945] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Aim: Coronary artery disease (CAD) is the result of a complex metabolic disorder caused by various environmental and genetic factors. Metabolomics is a potential tool for identifying biomarkers for better risk classification and for understanding the pathophysiological mechanisms of CAD. With this background, we performed a pilot study to identify metabolites associated with the future onset of CAD in patients with type 2 diabetes. Methods: Sixteen subjects who suffered from CAD event during the observation period and 39 non-CAD subjects who were matched to the CAD subjects for Framingham Coronary Heart Disease Risk Score, diabetes duration, and HbA1c were selected. Capillary electrophoresis time-of-flight mass spectrometry (CE-TOFMS) was used to perform non-targeted metabolome analysis of serum samples collected in 2005. Results: A total of 104 metabolites were identified. Unsupervised principal component analysis (PCA) did not to reveal two distinct clusters of individuals. However, a significant association with CAD was found for 7 metabolites (pelargonic acid, glucosamine:galactosamine, thymine, 3-hydroxybutyric acid, creatine, 2-aminoisobutyric acid, hypoxanthine) and the levels of all these metabolites were significantly lower in the CAD group compared with the non-CAD group. Conclusions: We identified 7 metabolites related to long-term future onset of CAD in Japanese patients with diabetes. Further studies with large sample size would be necessary to confirm our findings, and future studies using in vivo or in vitro models would be necessary to elucidate whether direct relationships exist between the detected metabolites and CAD pathophysiology.
Collapse
Affiliation(s)
- Kazuo Omori
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine
| | - Naoto Katakami
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine.,Department of Metabolism and Atherosclerosis, Osaka University Graduate School of Medicine
| | - Yuichi Yamamoto
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine
| | - Hiroyo Ninomiya
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine
| | - Mitsuyoshi Takahara
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine.,Department of Diabetes Care Medicine, Graduate, School of Medicine, Osaka University
| | - Taka-Aki Matsuoka
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine
| | - Takeshi Bamba
- Division of Metabolomics, Medical Institute of Bioregulation, Kyushu University
| | - Eiichiro Fukusaki
- Laboratory of Bioresource Engineering, Department of Biotechnology, Graduate School of Engineering, Osaka University
| | - Iichiro Shimomura
- Department of Metabolic Medicine, Osaka University Graduate School of Medicine
| |
Collapse
|
24
|
Salminen A, Vlachopoulou E, Havulinna AS, Tervahartiala T, Sattler W, Lokki ML, Nieminen MS, Perola M, Salomaa V, Sinisalo J, Meri S, Sorsa T, Pussinen PJ. Genetic Variants Contributing to Circulating Matrix Metalloproteinase 8 Levels and Their Association With Cardiovascular Diseases: A Genome-Wide Analysis. ACTA ACUST UNITED AC 2018; 10:CIRCGENETICS.117.001731. [PMID: 29212897 DOI: 10.1161/circgenetics.117.001731] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 09/11/2017] [Indexed: 11/16/2022]
Abstract
BACKGROUND Matrix metalloproteinase 8 (MMP-8) is a proinflammatory enzyme expressed mainly by neutrophils. Elevated serum and plasma concentrations of MMP-8 are associated with the risk for and outcome of cardiovascular diseases (CVDs). The origin of circulating MMP-8 is not completely clear. METHODS AND RESULTS We performed a genome-wide association study of serum MMP-8 levels in 2 populations comprising altogether 6049 individuals. Moreover, we studied whether MMP-8-associated variants are linked to increased risk of CVDs and overall mortality in >20 000 subjects. The strongest association with serum MMP-8 was found in locus 1q31.3, containing the gene for complement factor H (lead single nucleotide polymorphism: rs800292; P=2.4×10-35). In functional experiments, activation of the alternative pathway of complement in the carriers of rs800292 minor allele (Ile62 in factor H) led to decreased release of MMP-8 from neutrophils compared with the major allele (Val62 in factor H). Another association was detected in 1q21.3, containing genes S100A8, S100A9, and S100A12 (strongest association: rs1560833; P=5.3×10-15). The minor allele of rs1560833 was inversely associated with CVD (odds ratio [95% confidence interval]: 0.90 [0.82-0.99]; P=0.032) and the time to incident CVD event (hazard ratio [95% confidence interval]: 0.91 [0.84-0.99]; P=0.032) in men but not in women. CONCLUSIONS According to our results, the activation of the alternative pathway of the complement system strongly contributes to serum MMP-8 concentration. Genetic polymorphism in S100A9-S100A12-S100A8 locus affects serum and plasma MMP-8 and shows a suggestive association with the risk of CVDs. Our results show that genetic variation determines a significant portion of circulating MMP-8 concentrations.
Collapse
Affiliation(s)
- Aino Salminen
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.).
| | - Efthymia Vlachopoulou
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Aki S Havulinna
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Taina Tervahartiala
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Wolfgang Sattler
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Marja-Liisa Lokki
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Markku S Nieminen
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Markus Perola
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Veikko Salomaa
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Juha Sinisalo
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Seppo Meri
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Timo Sorsa
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| | - Pirkko J Pussinen
- From the Department of Oral and Maxillofacial Diseases (A.S., T.T., T.S., P.J.P.), Transplantation Laboratory, Medicum (E.V., M.-L.L.), Institute for Molecular Medicine Finland (M.P.), Immunobiology Research Program, Research Programs Unit (S.M.), and Department of Bacteriology and Immunology, Haartman Institute (S.M.), University of Helsinki, Finland; Department of Oral and Maxillofacial Diseases, Helsinki University Hospital, Finland (A.S., T.T., T.S., P.J.P.); Division of Periodontology, Department of Dental Medicine, Karolinska Institute, Huddinge, Sweden (A.S., T.S.); Department of Health, National Institute for Health and Welfare, Helsinki, Finland (A.S.H., M.P., V.S.); Institute of Molecular Biology and Biochemistry, Medical University of Graz, Austria (W.S.); and Division of Cardiology, HUCH Heart and Lung Center, Helsinki University Hospital, Finland (M.S.N., J.S.)
| |
Collapse
|
25
|
Yao S, Hong CC, Ruiz-Narváez EA, Evans SS, Zhu Q, Schaefer BA, Yan L, Coignet MV, Lunetta KL, Sucheston-Campbell LE, Lee K, Bandera EV, Troester MA, Rosenberg L, Palmer JR, Olshan AF, Ambrosone CB. Genetic ancestry and population differences in levels of inflammatory cytokines in women: Role for evolutionary selection and environmental factors. PLoS Genet 2018; 14:e1007368. [PMID: 29879116 PMCID: PMC5991662 DOI: 10.1371/journal.pgen.1007368] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2017] [Accepted: 04/18/2018] [Indexed: 01/09/2023] Open
Abstract
Selection pressure due to exposure to infectious pathogens endemic to Africa may explain distinct genetic variations in immune response genes. However, the impact of those genetic variations on human immunity remains understudied, especially within the context of modern lifestyles and living environments, which are drastically different from early humans in sub Saharan Africa. There are few data on population differences in constitutional immune environment, where genetic ancestry and environment are likely two primary sources of variation. In a study integrating genetic, molecular and epidemiologic data, we examined population differences in plasma levels of 14 cytokines involved in innate and adaptive immunity, including those implicated in chronic inflammation, and possible contributing factors to such differences, in 914 AA and 855 EA women. We observed significant differences in 7 cytokines, including higher plasma levels of CCL2, CCL11, IL4 and IL10 in EAs and higher levels of IL1RA and IFNα2 in AAs. Analyses of a wide range of demographic and lifestyle factors showed significant impact, with age, education level, obesity, smoking, and alcohol intake, accounting for some, but not all, observed population differences for the cytokines examined. Levels of two pro-inflammatory chemokines, CCL2 and CCL11, were strongly associated with percent of African ancestry among AAs. Through admixture mapping, the signal was pinpointed to local ancestry at 1q23, with fine-mapping analysis refined to the Duffy-null allele of rs2814778. In AA women, this variant was a major determinant of systemic levels of CCL2 (p = 1.1e-58) and CCL11 (p = 2.2e-110), accounting for 19% and 40% of the phenotypic variance, respectively. Our data reveal strong ancestral footprints in inflammatory chemokine regulation. The Duffy-null allele may indicate a loss of the buffering function for chemokine levels. The substantial immune differences by ancestry may have broad implications to health disparities between AA and EA populations.
Collapse
Affiliation(s)
- Song Yao
- Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Chi-Chen Hong
- Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Edward A. Ruiz-Narváez
- Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, MI, United States of America
| | - Sharon S. Evans
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Qianqian Zhu
- Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Beverly A. Schaefer
- Department of Pediatric Hematology & Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
- Department of Pediatric Hematology & Oncology, Jacobs School of Medicine and Biomedical Sciences, University of Buffalo, Buffalo, NY, United States of America
| | - Li Yan
- Department of Biostatistics and Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Marie V. Coignet
- Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Kathryn L. Lunetta
- Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America
| | | | - Kelvin Lee
- Department of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
| | - Elisa V. Bandera
- Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, The State University of New Jersey, New Brunswick, NJ, United States of America
| | - Melissa A. Troester
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America
| | - Lynn Rosenberg
- Slone Epidemiology Center at Boston University, Boston, MA, United States of America
| | - Julie R. Palmer
- Slone Epidemiology Center at Boston University, Boston, MA, United States of America
| | - Andrew F. Olshan
- Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America
| | - Christine B. Ambrosone
- Department of Cancer Prevention and Control, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States of America
- * E-mail:
| |
Collapse
|
26
|
Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J 2018; 285:2944-2971. [PMID: 29637711 PMCID: PMC6120486 DOI: 10.1111/febs.14466] [Citation(s) in RCA: 694] [Impact Index Per Article: 115.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2018] [Revised: 03/25/2018] [Accepted: 04/03/2018] [Indexed: 12/12/2022]
Abstract
The chemokines (or chemotactic cytokines) are a large family of small, secreted proteins that signal through cell surface G protein-coupled heptahelical chemokine receptors. They are best known for their ability to stimulate the migration of cells, most notably white blood cells (leukocytes). Consequently, chemokines play a central role in the development and homeostasis of the immune system, and are involved in all protective or destructive immune and inflammatory responses. Classically viewed as inducers of directed chemotactic migration, it is now clear that chemokines can stimulate a variety of other types of directed and undirected migratory behavior, such as haptotaxis, chemokinesis, and haptokinesis, in addition to inducing cell arrest or adhesion. However, chemokine receptors on leukocytes can do more than just direct migration, and these molecules can also be expressed on, and regulate the biology of, many nonleukocytic cell types. Chemokines are profoundly affected by post-translational modification, by interaction with the extracellular matrix (ECM), and by binding to heptahelical 'atypical' chemokine receptors that regulate chemokine localization and abundance. This guide gives a broad overview of the chemokine and chemokine receptor families; summarizes the complex physical interactions that occur in the chemokine network; and, using specific examples, discusses general principles of chemokine function, focusing particularly on their ability to direct leukocyte migration.
Collapse
Affiliation(s)
- Catherine E Hughes
- Institute of Infection, Inflammation & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
| | - Robert J B Nibbs
- Institute of Infection, Inflammation & Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK
| |
Collapse
|
27
|
Charles BA, Hsieh MM, Adeyemo AA, Shriner D, Ramos E, Chin K, Srivastava K, Zakai NA, Cushman M, McClure LA, Howard V, Flegel WA, Rotimi CN, Rodgers GP. Analyses of genome wide association data, cytokines, and gene expression in African-Americans with benign ethnic neutropenia. PLoS One 2018; 13:e0194400. [PMID: 29596498 PMCID: PMC5875757 DOI: 10.1371/journal.pone.0194400] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Accepted: 03/04/2018] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Benign ethnic neutropenia (BEN) is a hematologic condition associated with people of African ancestry and specific Middle Eastern ethnic groups. Prior genetic association studies in large population showed that rs2814778 in Duffy Antigen Receptor for Chemokines (DARC) gene, specifically DARC null red cell phenotype, was associated with BEN. However, the mechanism of this red cell phenotype leading to low white cell count remained elusive. METHODS We conducted an extreme phenotype design genome-wide association study (GWAS), analyzed ~16 million single nucleotide polymorphisms (SNP) in 1,178 African-Americans individuals from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study and replicated from 819 African-American participants in the Atherosclerosis Risk in Communities (ARIC) study. Conditional analyses on rs2814778 were performed to identify additional association signals on chromosome 1q22. In a separate cohort of healthy individuals with and without BEN, whole genome gene expression from peripheral blood neutrophils were analyzed for DARC. RESULTS We confirmed that rs2814778 in DARC was associated with BEN (p = 4.09×10-53). Conditioning on rs2814778 abolished other significant chromosome 1 associations. Inflammatory cytokines (IL-2, 6, and 10) in participants in the Howard University Family Study (HUFS) and Multi-Ethnic Study in Atherosclerosis (MESA) showed similar levels in individuals homozygous for the rs2814778 allele compared to others, indicating cytokine sink hypothesis played a minor role in leukocyte homeostasis. Gene expression in neutrophils of individuals with and without BEN was also similar except for low DARC expression in BEN, suggesting normal function. BEN neutrophils had slightly activated profiles in leukocyte migration and hematopoietic stem cell mobilization pathways (expression fold change <2). CONCLUSIONS These results in humans support the notion of DARC null erythroid progenitors preferentially differentiating to myeloid cells, leading to activated DARC null neutrophils egressing from circulation to the spleen, and causing relative neutropenia. Collectively, these human data sufficiently explained the mechanism DARC null red cell phenotype causing BEN and further provided a biologic basis that BEN is clinically benign.
Collapse
Affiliation(s)
- Bashira A. Charles
- Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
| | - Matthew M. Hsieh
- Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, United States of America
| | - Adebowale A. Adeyemo
- Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
| | - Daniel Shriner
- Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
| | - Edward Ramos
- Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
- National Institute of Biomedical Imaging and Bioengineering, NIH, Bethesda, Maryland, United States of America
| | - Kyung Chin
- Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, United States of America
| | - Kshitij Srivastava
- Warren Grant Magnuson Clinical Center, NIH, Bethesda, Maryland, United States of America
| | - Neil A. Zakai
- Departments of Pathology and Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America
| | - Mary Cushman
- Departments of Pathology and Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, United States of America
| | - Leslie A. McClure
- School of Public Health, University of Alabama, Birmingham, Alabama, United States of America
- Department of Epidemiology and Biostatistics, Drexel University, Philadelphia, Pennsylvania, United States of America
| | - Virginia Howard
- School of Public Health, University of Alabama, Birmingham, Alabama, United States of America
| | - Willy A. Flegel
- Warren Grant Magnuson Clinical Center, NIH, Bethesda, Maryland, United States of America
| | - Charles N. Rotimi
- Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health (NIH), Bethesda, Maryland, United States of America
- * E-mail: (CNR); (GPR)
| | - Griffin P. Rodgers
- Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, Maryland, United States of America
- * E-mail: (CNR); (GPR)
| |
Collapse
|
28
|
Karsten E, Breen E, Herbert BR. Red blood cells are dynamic reservoirs of cytokines. Sci Rep 2018; 8:3101. [PMID: 29449599 PMCID: PMC5814557 DOI: 10.1038/s41598-018-21387-w] [Citation(s) in RCA: 70] [Impact Index Per Article: 11.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2017] [Accepted: 01/24/2018] [Indexed: 01/06/2023] Open
Abstract
Red blood cells (RBCs) have been shown to affect immune function and can induce inflammatory responses after transfusion. The transfusion of washed RBCs can significantly reduce adverse effects, however, the soluble factors that may mediate these effects have not been identified. Previous studies have identified, but not quantified, a small number of chemokines associated with RBCs. We isolated RBCs from healthy volunteers and quantified of a panel of 48 cytokines, chemokines, and growth factors in the lysate, cytosol, and conditioned media of these cells using Luminex® technology. This analysis revealed that, after correcting for white blood cell and platelet contamination, 46 cytokines were detected in RBC lysates, and the median concentration in RBCs was 12-fold higher than in the plasma. In addition, extensive washing of RBCs, such as that performed in proteomics analyses or prior to some RBC transfusions, significantly attenuated the release of six cytokines following incubation at 37 °C. This supports the hypothesis that, alongside its gas exchange function, RBCs play a role in cytokine signalling. This discovery may help supplement disease biomarker research and may shed light on adverse inflammatory processes that can follow RBC transfusion.
Collapse
Affiliation(s)
- Elisabeth Karsten
- Translational Regenerative Medicine Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia. .,Northern Clinical School, Faculty of Medicine, The University of Sydney, Sydney, Australia. .,Sangui Bio Pty Ltd, Sydney, Australia.
| | | | - Benjamin R Herbert
- Translational Regenerative Medicine Laboratory, Kolling Institute, Royal North Shore Hospital, Sydney, Australia.,Northern Clinical School, Faculty of Medicine, The University of Sydney, Sydney, Australia.,Sangui Bio Pty Ltd, Sydney, Australia
| |
Collapse
|
29
|
Kaluarachchi M, Boulangé CL, Karaman I, Lindon JC, Ebbels TMD, Elliott P, Tracy RP, Olson NC. A comparison of human serum and plasma metabolites using untargeted 1H NMR spectroscopy and UPLC-MS. Metabolomics 2018; 14:32. [PMID: 30830335 PMCID: PMC7122646 DOI: 10.1007/s11306-018-1332-1] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2017] [Accepted: 01/30/2018] [Indexed: 12/21/2022]
Abstract
INTRODUCTION Differences in the metabolite profiles between serum and plasma are incompletely understood. OBJECTIVES To evaluate metabolic profile differences between serum and plasma and among plasma sample subtypes. METHODS We analyzed serum, platelet rich plasma (PRP), platelet poor plasma (PPP), and platelet free plasma (PFP), collected from 8 non-fasting apparently healthy women, using untargeted standard 1D and CPMG 1H NMR and reverse phase and hydrophilic (HILIC) UPLC-MS. Differences between metabolic profiles were evaluated using validated principal component and orthogonal partial least squares discriminant analysis. RESULTS Explorative analysis showed the main source of variation among samples was due to inter-individual differences with no grouping by sample type. After correcting for inter-individual differences, lipoproteins, lipids in VLDL/LDL, lactate, glutamine, and glucose were found to discriminate serum from plasma in NMR analyses. In UPLC-MS analyses, lysophosphatidylethanolamine (lysoPE)(18:0) and lysophosphatidic acid(20:0) were higher in serum, and phosphatidylcholines (PC)(16:1/18:2, 20:3/18:0, O-20:0/22:4), lysoPC(16:0), PE(O-18:2/20:4), sphingomyelin(18:0/22:0), and linoleic acid were lower. In plasma subtype analyses, isoleucine, leucine, valine, phenylalanine, glutamate, and pyruvate were higher among PRP samples compared with PPP and PFP by NMR while lipids in VLDL/LDL, citrate, and glutamine were lower. By UPLC-MS, PE(18:0/18:2) and PC(P-16:0/20:4) were higher in PRP compared with PFP samples. CONCLUSIONS Correction for inter-individual variation was required to detect metabolite differences between serum and plasma. Our results suggest the potential importance of inter-individual effects and sample type on the results from serum and plasma metabolic phenotyping studies.
Collapse
Affiliation(s)
- Manuja Kaluarachchi
- Metabometrix Ltd, Sir Alexander Fleming Building, Prince Consort Road, London, SW7 1BP, UK
| | - Claire L Boulangé
- Metabometrix Ltd, Sir Alexander Fleming Building, Prince Consort Road, London, SW7 1BP, UK
| | - Ibrahim Karaman
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK
| | - John C Lindon
- Metabometrix Ltd, Sir Alexander Fleming Building, Prince Consort Road, London, SW7 1BP, UK
- Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, SW7 2AZ, UK
| | - Timothy M D Ebbels
- Computational and Systems Medicine, Department of Surgery and Cancer, Imperial College London, London, SW7 2AZ, UK
| | - Paul Elliott
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK
- MRC-PHE Centre for Environment and Health, Imperial College London, London, W2 1PG, UK
| | - Russell P Tracy
- Department of Biochemistry, The Robert Larner, M.D. College of Medicine at The University of Vermont, Burlington, VT, 05446, USA
- Department of Pathology and Laboratory Medicine, The Robert Larner, M.D. College of Medicine at The University of Vermont, Burlington, VT, 05446, USA
| | - Nels C Olson
- Department of Pathology and Laboratory Medicine, The Robert Larner, M.D. College of Medicine at The University of Vermont, Burlington, VT, 05446, USA.
| |
Collapse
|
30
|
Davison GM, Hendrickse HL, Matsha TE. The relationship between immunogenic red blood cell antigens and Human Immunodeficiency Virus infection. Transfus Apher Sci 2017; 57:58-62. [PMID: 29269123 DOI: 10.1016/j.transci.2017.11.033] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Revised: 11/21/2017] [Accepted: 11/28/2017] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Evidence suggests that red cell antigens may act as receptors for viruses and bacteria and therefore could be associated with HIV infection. Previous studies have been controversial and therefore the aim of this exploratory study was to analyse the expression of immunogenic red cell antigens in HIV-seropositive individuals and to compare the results to negative donors from South Africa. METHODS The expression of ABO, Rh, Kell and Duffy antigens from 119 HIV-seropositive patients was compared to 317 HIV-seronegative blood donors. Nucleic acid amplification testing and PCR were used to determine the HIV status and the ID-Gel Card Technology was used to determine the blood group antigen profile. RESULTS There was no significant difference in the expression of A, B, AB, Duffy or Kel antigens between the two groups but significantly lower numbers of HIV+ individuals were O Rh Negative (p = ,0.0001). Analysis of those with a Duffy null phenotype revealed a significantly higher incidence of blood type A RH1-Positive, Dce/R0r and B RH1-Positive, DcEe/R2r within the HIV-seropositive group (p = < 0.05). None of the HIV-seropositive individuals were O RH1-Negative, dce/rr. CONCLUSION In conclusion these initial findings have demonstrated a decreased incidence of blood type O Rh1-negative in HIV + individuals which suggests that red blood cell antigens may play an important role in susceptibility to HIV infection. The relationship between red cell antigens and HIV infection however remains complex and therefore larger studies are required to confirm these results.
Collapse
Affiliation(s)
- Glenda M Davison
- Department of Biomedical sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, South Africa.
| | - Heather L Hendrickse
- Department of Biomedical sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, South Africa
| | - Tandi E Matsha
- Department of Biomedical sciences, Faculty of Health and Wellness Sciences, Cape Peninsula University of Technology, Bellville, South Africa
| |
Collapse
|
31
|
Shao LN, Zhang ST, Zhou SH, Yu WJ, Liu M. Atypical Chemokine Receptor 1 polymorphism cannot be used as an indicator of liver fibrosis progression in Hepatitis C virus positive patients. Pak J Med Sci 2017; 33:1134-1137. [PMID: 29142552 PMCID: PMC5673721 DOI: 10.12669/pjms.335.12590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
Abstract
Background & Objective: Atypical chemokine receptor 1(ACKR1) represents an atypical chemokine receptor that can bind promiscuously to various chemokines. Chemokines play a crucial role to recruit leukocyte subsets migration through the endothelium and into liver against the virus during the progression of hepatitis C virus (HCV) infection. Most HCV positive patients can lead to liver fibrosis. Hyaluronic acid (HA), laminin (LN), collagen IV(C-IV) and amino-terminal pro-peptide of Type-III pro-collagen (PIII NP) are indices of the extent of liver fibrosis. The aim of this study was to investigate the association between ACKR1 polymorphism and liver fibrosis with these four serum liver markers in HCV positive patients. Methods: From April 2015 to December 2015, a total of 210 patients (109 males and 101 females) with chronic HCV infection at Dalian Infectious Hospital were recruited to participate in this study. ACKR1 genotyping was using TaqMan probes method. HA, LN, C-IV and PIII NP were detected by using diagnostic kits. Results: We compared serum levels of HA, LN, C-IV and PIII NP between FY*A/FY*A and FY*A/FY*B patients and the differences were not significant (P=0.905, P=0.298, P=0.880 and P=0.470, respectively). Conclusions: This study has attempted to elucidate the role of ACKR1 polymorphism in liver fibrosis progression of HCV infection, our results demonstrated that ACKR1 polymorphism is not directly associated with the fibrogenesis in HCV positive patients.
Collapse
Affiliation(s)
- Lin-Nan Shao
- Lin-Nan Shao, Dalian Blood Center, Dalian, Liaoning, 116001, China
| | - Shu-Ting Zhang
- Shu-Ting Zhang, Dalian Blood Center, Dalian, Liaoning, 116001, China
| | - Shi-Hang Zhou
- Shi-Hang Zhou, Dalian Blood Center, Dalian, Liaoning, 116001, China
| | - Wei-Jian Yu
- Wei-Jian Yu, Dalian Blood Center, Dalian, Liaoning, 116001, China
| | - Ming Liu
- Ming Liu, Department of Cell Biology, Dalian Medical University, Dalian, 116044, China
| |
Collapse
|
32
|
Chapman DG, Mougey EB, Van der Velden JL, Lahue KG, Aliyeva M, Daphtary N, George KL, Hoffman SM, Schneider RW, Tracy RP, Worthen GS, Poynter ME, Peters SP, Lima JJ, Janssen-Heininger YMW, Irvin CG. The Duffy antigen receptor for chemokines regulates asthma pathophysiology. Clin Exp Allergy 2017; 47:1214-1222. [PMID: 28471517 PMCID: PMC5578916 DOI: 10.1111/cea.12949] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Revised: 03/21/2017] [Accepted: 03/27/2017] [Indexed: 12/14/2022]
Abstract
BACKGROUND The Duffy antigen receptor for chemokines (DARC) is an atypical receptor that regulates pro-inflammatory cytokines. However, the role of DARC in asthma pathophysiology is unknown. OBJECTIVE To determine the role of DARC in allergic airways disease in mice, and the association between DARC single nucleotide polymorphisms (SNPs) and clinical outcomes in patients with asthma. METHODS Mice with targeted disruption of the Darc gene (Darc∆E2 ) or WT mice were challenged over 3 weeks with house dust mite (HDM) antigen. Allergic airways disease was assessed 24 hours and 7 days following the final challenge. Additionally, associations between DARC SNPs and clinical outcomes were analysed in a cohort of poorly controlled asthmatics. RESULTS Total airway inflammation following HDM did not differ between Darc∆E2 and WT mice. At 24 hours, Darc∆E2 mice had increased airway hyperresponsiveness; however, at 7 days airway hyperresponsiveness had completely resolved in Darc∆E2 but persisted in WT mice. In poorly controlled asthmatics, DARC SNPs were associated with worse asthma control at randomization and subsequent increased risk of healthcare utilization (odds ratio 3.13(1.37-7.27), P=.0062). CONCLUSIONS AND CLINICAL RELEVANCE Our animal model and human patient data suggest a novel role for DARC in the temporal regulation in asthma pathophysiology and symptoms.
Collapse
Affiliation(s)
- D G Chapman
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
- Woolcock Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, NSW, Australia
| | - E B Mougey
- Nemours Pharmacogenetics Center, Nemours Children's Clinic, Jacksonville, FL, USA
| | - J L Van der Velden
- Department of Pathology, University of Vermont College of Medicine, Burlington, VT, USA
| | - K G Lahue
- Department of Pathology, University of Vermont College of Medicine, Burlington, VT, USA
| | - M Aliyeva
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
| | - N Daphtary
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
| | - K L George
- Nemours Pharmacogenetics Center, Nemours Children's Clinic, Jacksonville, FL, USA
| | - S M Hoffman
- Department of Pathology, University of Vermont College of Medicine, Burlington, VT, USA
| | - R W Schneider
- Department of Pathology, University of Vermont College of Medicine, Burlington, VT, USA
| | - R P Tracy
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
- Department of Biochemistry, University of Vermont College of Medicine, Burlington, VT, USA
| | - G S Worthen
- Children's Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA, USA
| | - M E Poynter
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
| | - S P Peters
- Section on Pulmonary, Critical Care, Allergy & Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA
| | - J J Lima
- Nemours Pharmacogenetics Center, Nemours Children's Clinic, Jacksonville, FL, USA
| | | | - C G Irvin
- Department of Medicine, University of Vermont College of Medicine, Burlington, VT, USA
| |
Collapse
|
33
|
Zhang ST, Shi M, Shao LN, Zhou SH, Yu WJ, Chen M, Xiao N, Duan Y, Pan LZ, Wang N, Song WQ, Xia YX, Zhang L, Qi N, Liu M. Atypical Chemokine Receptor 1 Polymorphism can not Affect Susceptibility to Hepatitis C Virus. Balkan Med J 2017; 34:308-312. [PMID: 28443566 PMCID: PMC5615962 DOI: 10.4274/balkanmedj.2016.0766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
Abstract
Background: Hepatitis C virus has infected 130 to 150 million individuals globally. Atypical chemokine receptor 1 has become a focus of research because of its diverse roles in different diseases. However, little is known regarding the association of atypical chemokine receptor 1 polymorphism with susceptibility to hepatitis C virus. Aims: To determine the association of an atypical chemokine receptor 1 polymorphism (rs12075) with hepatitis C virus susceptibility. Study Design: Case-control study. Methods: We collected blood samples from 231 patients infected with hepatitis C virus and 239 blood donors as control subjects. Genotyping of atypical chemokine receptor 1 was performed using a 5ˊ-nuclease assay with TaqMan-minor groove binding probes. Comparisons between hepatitis C virus-infected patients and control subjects were assessed using Fisher’s exact test. Results: The genotype frequencies of FY*A/FY*A, FY*A/FY*B and FY*B/FY*B were 86.1%, 13.9% and 0% in the patient group, and 86.2%, 13.4% and 0.4% in the control group, respectively. The difference in atypical chemokine receptor 1 genotype frequencies between hepatitis C virus-infected patients and control group was not significant (p=1.00, OR=1.004, 95% CI=0.594-1.695). FY*A and FY*B allele frequencies were 93.1% and 6.9% in the patient group, and 92.9% and 7.1% in the control group, respectively. The difference in atypical chemokine receptor 1 allele frequencies between hepatitis C virus-infected patients and the control group was not significant (p=1.00, OR=0.972, 95% CI=0.589-1.603). Conclusion: Our result indicates that atypical chemokine receptor 1 polymorphism (rs12075) does not affect susceptibility to hepatitis C virus.
Collapse
Affiliation(s)
| | - Ming Shi
- Dalian University School of Medicine, Liaoning, China
| | | | | | | | - Mei Chen
- Dalian Blood Center, Liaoning, China
| | - Nan Xiao
- Dalian Blood Center, Liaoning, China
| | - Ying Duan
- Dalian Blood Center, Liaoning, China
| | | | - Ni Wang
- Dalian Blood Center, Liaoning, China
| | | | | | - Li Zhang
- Dalian Blood Center, Liaoning, China
| | - Ning Qi
- Dalian Blood Center, Liaoning, China
| | - Ming Liu
- Department of Cell Biology, Dalian Medical University, Liaoning, China
| |
Collapse
|
34
|
da Silva-Malta MCF, Sales CC, Guimarães JC, de Cássia Gonçalves P, Chaves DG, Santos HC, da Costa Pereira A, Ribas JG, de Freitas Carneiro-Proietti AB, Martins ML. The Duffy null genotype is associated with a lower level of CCL2, leukocytes and neutrophil count but not with the clinical outcome of HTLV-1 infection. J Med Microbiol 2017; 66:1207-1216. [DOI: 10.1099/jmm.0.000539] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Affiliation(s)
| | - Camila Campos Sales
- Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Minas, Gerais, Brazil
| | | | | | - Daniel Gonçalves Chaves
- Serviço de Pesquisa, Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil
- Interdisciplinary HTLV Research Group (GIPH), Brazil
| | - Hadassa Campos Santos
- Laboratório de Genética e Cardiologia Molecular, Instituto do Coração, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - Alexandre da Costa Pereira
- Laboratório de Genética e Cardiologia Molecular, Instituto do Coração, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | | | | | - Marina Lobato Martins
- Interdisciplinary HTLV Research Group (GIPH), Brazil
- Serviço de Pesquisa, Fundação Hemominas, Belo Horizonte, Minas Gerais, Brazil
| |
Collapse
|
35
|
Duchene J, Novitzky-Basso I, Thiriot A, Casanova-Acebes M, Bianchini M, Etheridge SL, Hub E, Nitz K, Artinger K, Eller K, Caamaño J, Rülicke T, Moss P, Megens RTA, von Andrian UH, Hidalgo A, Weber C, Rot A. Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesis. Nat Immunol 2017; 18:753-761. [PMID: 28553950 PMCID: PMC5480598 DOI: 10.1038/ni.3763] [Citation(s) in RCA: 62] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2017] [Accepted: 04/28/2017] [Indexed: 12/14/2022]
Abstract
Healthy individuals of African ancestry have neutropenia that has been linked with the variant rs2814778(G) of the gene encoding atypical chemokine receptor 1 (ACKR1). This polymorphism selectively abolishes the expression of ACKR1 in erythroid cells, causing a Duffy-negative phenotype. Here we describe an unexpected fundamental role for ACKR1 in hematopoiesis and provide the mechanism that links its absence with neutropenia. Nucleated erythroid cells had high expression of ACKR1, which facilitated their direct contact with hematopoietic stem cells. The absence of erythroid ACKR1 altered mouse hematopoiesis including stem and progenitor cells, which ultimately gave rise to phenotypically distinct neutrophils that readily left the circulation, causing neutropenia. Individuals with a Duffy-negative phenotype developed a distinct profile of neutrophil effector molecules that closely reflected the one observed in the ACKR1-deficient mice. Thus, alternative physiological patterns of hematopoiesis and bone marrow cell outputs depend on the expression of ACKR1 in the erythroid lineage, findings with major implications for the selection advantages that have resulted in the paramount fixation of the ACKR1 rs2814778(G) polymorphism in Africa.
Collapse
Affiliation(s)
- Johan Duchene
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
| | - Igor Novitzky-Basso
- Blood and Marrow Transplant Unit, Queen Elizabeth University Hospital, Glasgow UK
| | - Aude Thiriot
- Department of Microbiology and Immunobiology and Center for Immune Imaging, Harvard Medical School, Boston, MA, USA
- The Ragon Institute, Cambridge, MA, USA
| | - Maria Casanova-Acebes
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Mariaelvy Bianchini
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
| | - S. Leah Etheridge
- Centre for Immunology and Infection, Department of Biology, University of York, Heslington, York, UK
| | - Elin Hub
- Centre for Immunology and Infection, Department of Biology, University of York, Heslington, York, UK
| | - Katrin Nitz
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
- Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany
| | - Katharina Artinger
- Centre for Immunology and Infection, Department of Biology, University of York, Heslington, York, UK
- Clinical Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Kathrin Eller
- Clinical Division of Nephrology, Department of Internal Medicine, Medical University of Graz, Graz, Austria
| | - Jorge Caamaño
- Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - Thomas Rülicke
- Institute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, Austria
| | - Paul Moss
- Institute of Immunology and Immunotherapy, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
| | - Remco T. A. Megens
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
- Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
| | - Ulrich H. von Andrian
- Department of Microbiology and Immunobiology and Center for Immune Imaging, Harvard Medical School, Boston, MA, USA
- The Ragon Institute, Cambridge, MA, USA
| | - Andres Hidalgo
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain
| | - Christian Weber
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
- Cardiovascular Research Institute Maastricht, University of Maastricht, Maastricht, The Netherlands
| | - Antal Rot
- Institute for Cardiovascular Prevention, Ludwig-Maximilians-University, Munich, Germany
- Centre for Immunology and Infection, Department of Biology, University of York, Heslington, York, UK
- Center for Advanced Studies, Ludwig-Maximilians-University, Munich, Germany
- Address from July 2017: William Harvey Research Institute, Queen Mary University of London. London, UK
| |
Collapse
|
36
|
Martins ML, da Silva AR, Santos HC, Alves MT, Schmidt LC, Vertchenko SB, Dusse LMS, Silva Malta MCFD. Duffy blood group system: New genotyping method and distribution in a Brazilian extra-Amazonian population. Mol Cell Probes 2017; 35:20-26. [PMID: 28587995 DOI: 10.1016/j.mcp.2017.06.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Revised: 05/18/2017] [Accepted: 06/02/2017] [Indexed: 11/28/2022]
Abstract
Duffy blood group system is of interest in several fields of science including transfusion medicine, immunology and malariology. Although some methods have been developed for Duffy polymorphism genotyping, not all of them have been sufficiently described and validated, and all present limitations. At the same time, the frequency of Duffy alleles and antigens in some densely populated regions of the world are still missing. In this study we present new tests for genotyping the major alleles of the Duffy blood system and describe Duffy alleles and antigens in blood donors and transfusion-dependent patients in Minas Gerais, Brazil. A simple and reproducible strategy was devised for Duffy genotyping based on real-time PCR that included SNPs rs12075 and rs2814778. No significant differences between the allele frequencies were observed comparing blood donors and patients. Among the blood donors, the phenotype Fy(a-b+) was the most common and the Fy(a-b-) phenotype, associated with populations of African descent, was remarkably less common among subjects who self-identified as black in comparison to other ethnoracial categories. However, the African ancestry estimated by molecular markers was significantly higher in individuals with the allele associated to the Duffy null phenotype. The genotyping method presented may be useful to study Duffy genotypes accurately in different contexts and populations. The results suggest a reduced risk of alloimmunization for Duffy antigens and increased susceptibility for malaria in Minas Gerais, considering the high frequency of Duffy-positive individuals.
Collapse
Affiliation(s)
- Marina Lobato Martins
- Fundação Centro de Hematologia e Hemoterapia de Minas Gerais - Hemominas, MG, Brazil
| | - Adão Rogerio da Silva
- Fundação Centro de Hematologia e Hemoterapia de Minas Gerais - Hemominas, MG, Brazil; Department of Clinical and Toxicological Analysis, Faculty of Pharmacy - Universidade Federal de Minas Gerais, Brazil
| | - Hadassa Campos Santos
- Laboratório de Genética e Cardiologia Molecular, Instituto do Coração, Faculdade de Medicina da Universidade de São Paulo, Brazil
| | | | | | | | - Luci Maria SantAna Dusse
- Department of Clinical and Toxicological Analysis, Faculty of Pharmacy - Universidade Federal de Minas Gerais, Brazil
| | | |
Collapse
|
37
|
Salvi V, Sozio F, Sozzani S, Del Prete A. Role of Atypical Chemokine Receptors in Microglial Activation and Polarization. Front Aging Neurosci 2017; 9:148. [PMID: 28603493 PMCID: PMC5445112 DOI: 10.3389/fnagi.2017.00148] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2017] [Accepted: 05/02/2017] [Indexed: 01/07/2023] Open
Abstract
Inflammatory reactions occurring in the central nervous system (CNS), known as neuroinflammation, are key components of the pathogenic mechanisms underlying several neurological diseases. The chemokine system plays a crucial role in the recruitment and activation of immune and non-immune cells in the brain, as well as in the regulation of microglia phenotype and function. Chemokines belong to a heterogeneous family of chemotactic agonists that signal through the interaction with G protein-coupled receptors (GPCRs). Recently, a small subset of chemokine receptors, now identified as “atypical chemokine receptors” (ACKRs), has been described. These receptors lack classic GPCR signaling and chemotactic activity and are believed to limit inflammation through their ability to scavenge chemokines at the inflammatory sites. Recent studies have highlighted a role for ACKRs in neuroinflammation. However, in the CNS, the role of ACKRs seems to be more complex than the simple control of inflammation. For instance, CXCR7/ACKR3 was shown to control T cell trafficking through the regulation of CXCL12 internalization at CNS endothelial barriers. Furthermore, D6/ACKR2 KO mice were protected in a model of experimental autoimmune encephalomyelitis (EAE). D6/ACKR2 KO showed an abnormal accumulation of dendritic cells at the immunization and a subsequent impairment in T cell priming. Finally, CCRL2, an ACKR-related protein, was shown to play a role in the control of the resolution phase of EAE. Indeed, CCRL2 KO mice showed exacerbated, non-resolving disease with protracted inflammation and increased demyelination. This phenotype was associated with increased microglia and macrophage activation markers and imbalanced M1 vs. M2 polarization. This review will summarize the current knowledge on the role of the ACKRs in neuroinflammation with a particular attention to their role in microglial polarization and function.
Collapse
Affiliation(s)
- Valentina Salvi
- Department of Molecular and Translational Medicine, University of BresciaBrescia, Italy
| | - Francesca Sozio
- Department of Molecular and Translational Medicine, University of BresciaBrescia, Italy.,IRCCS-Humanitas Clinical and Research CenterRozzano-Milano, Italy
| | - Silvano Sozzani
- Department of Molecular and Translational Medicine, University of BresciaBrescia, Italy.,IRCCS-Humanitas Clinical and Research CenterRozzano-Milano, Italy
| | - Annalisa Del Prete
- Department of Molecular and Translational Medicine, University of BresciaBrescia, Italy.,IRCCS-Humanitas Clinical and Research CenterRozzano-Milano, Italy
| |
Collapse
|
38
|
Impact of genetic polymorphisms determining leukocyte/neutrophil count on chemotherapy toxicity. THE PHARMACOGENOMICS JOURNAL 2017; 18:270-274. [DOI: 10.1038/tpj.2017.16] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 02/23/2017] [Accepted: 03/02/2017] [Indexed: 12/22/2022]
|
39
|
Ahola-Olli AV, Würtz P, Havulinna AS, Aalto K, Pitkänen N, Lehtimäki T, Kähönen M, Lyytikäinen LP, Raitoharju E, Seppälä I, Sarin AP, Ripatti S, Palotie A, Perola M, Viikari JS, Jalkanen S, Maksimow M, Salomaa V, Salmi M, Kettunen J, Raitakari OT. Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors. Am J Hum Genet 2017; 100:40-50. [PMID: 27989323 DOI: 10.1016/j.ajhg.2016.11.007] [Citation(s) in RCA: 332] [Impact Index Per Article: 47.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2016] [Accepted: 11/11/2016] [Indexed: 12/14/2022] Open
Abstract
Circulating cytokines and growth factors are regulators of inflammation and have been implicated in autoimmune and metabolic diseases. In this genome-wide association study (GWAS) of up to 8,293 Finns we identified 27 genome-widely significant loci (p < 1.2 × 10-9) for one or more cytokines. Fifteen of the associated variants had expression quantitative trait loci in whole blood. We provide genetic instruments to clarify the causal roles of cytokine signaling and upstream inflammation in immune-related and other chronic diseases. We further link inflammatory markers with variants previously associated with autoimmune diseases such as Crohn disease, multiple sclerosis, and ulcerative colitis and hereby elucidate the molecular mechanisms underpinning these diseases and suggest potential drug targets.
Collapse
|
40
|
MacNamara KC. Shedding light on HSC dormancy-a role for the DARC. Stem Cell Investig 2016; 3:40. [PMID: 27668247 DOI: 10.21037/sci.2016.08.06] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2016] [Accepted: 08/10/2016] [Indexed: 11/06/2022]
Affiliation(s)
- Katherine C MacNamara
- Department of Immunology and Microbial Disease, Albany Medical College, 47 New Scotland Avenue, Albany, NY 12208, USA
| |
Collapse
|
41
|
Chami N, Chen MH, Slater AJ, Eicher JD, Evangelou E, Tajuddin SM, Love-Gregory L, Kacprowski T, Schick UM, Nomura A, Giri A, Lessard S, Brody JA, Schurmann C, Pankratz N, Yanek LR, Manichaikul A, Pazoki R, Mihailov E, Hill WD, Raffield LM, Burt A, Bartz TM, Becker DM, Becker LC, Boerwinkle E, Bork-Jensen J, Bottinger EP, O'Donoghue ML, Crosslin DR, de Denus S, Dubé MP, Elliott P, Engström G, Evans MK, Floyd JS, Fornage M, Gao H, Greinacher A, Gudnason V, Hansen T, Harris TB, Hayward C, Hernesniemi J, Highland HM, Hirschhorn JN, Hofman A, Irvin MR, Kähönen M, Lange E, Launer LJ, Lehtimäki T, Li J, Liewald DCM, Linneberg A, Liu Y, Lu Y, Lyytikäinen LP, Mägi R, Mathias RA, Melander O, Metspalu A, Mononen N, Nalls MA, Nickerson DA, Nikus K, O'Donnell CJ, Orho-Melander M, Pedersen O, Petersmann A, Polfus L, Psaty BM, Raitakari OT, Raitoharju E, Richard M, Rice KM, Rivadeneira F, Rotter JI, Schmidt F, Smith AV, Starr JM, Taylor KD, Teumer A, Thuesen BH, Torstenson ES, Tracy RP, Tzoulaki I, Zakai NA, Vacchi-Suzzi C, van Duijn CM, van Rooij FJA, Cushman M, Deary IJ, Velez Edwards DR, Vergnaud AC, Wallentin L, Waterworth DM, White HD, Wilson JG, Zonderman AB, Kathiresan S, Grarup N, Esko T, Loos RJF, Lange LA, Faraday N, Abumrad NA, Edwards TL, Ganesh SK, Auer PL, Johnson AD, Reiner AP, Lettre G. Exome Genotyping Identifies Pleiotropic Variants Associated with Red Blood Cell Traits. Am J Hum Genet 2016; 99:8-21. [PMID: 27346685 PMCID: PMC5005438 DOI: 10.1016/j.ajhg.2016.05.007] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2016] [Accepted: 05/03/2016] [Indexed: 11/24/2022] Open
Abstract
Red blood cell (RBC) traits are important heritable clinical biomarkers and modifiers of disease severity. To identify coding genetic variants associated with these traits, we conducted meta-analyses of seven RBC phenotypes in 130,273 multi-ethnic individuals from studies genotyped on an exome array. After conditional analyses and replication in 27,480 independent individuals, we identified 16 new RBC variants. We found low-frequency missense variants in MAP1A (rs55707100, minor allele frequency [MAF] = 3.3%, p = 2 × 10(-10) for hemoglobin [HGB]) and HNF4A (rs1800961, MAF = 2.4%, p < 3 × 10(-8) for hematocrit [HCT] and HGB). In African Americans, we identified a nonsense variant in CD36 associated with higher RBC distribution width (rs3211938, MAF = 8.7%, p = 7 × 10(-11)) and showed that it is associated with lower CD36 expression and strong allelic imbalance in ex vivo differentiated human erythroblasts. We also identified a rare missense variant in ALAS2 (rs201062903, MAF = 0.2%) associated with lower mean corpuscular volume and mean corpuscular hemoglobin (p < 8 × 10(-9)). Mendelian mutations in ALAS2 are a cause of sideroblastic anemia and erythropoietic protoporphyria. Gene-based testing highlighted three rare missense variants in PKLR, a gene mutated in Mendelian non-spherocytic hemolytic anemia, associated with HGB and HCT (SKAT p < 8 × 10(-7)). These rare, low-frequency, and common RBC variants showed pleiotropy, being also associated with platelet, white blood cell, and lipid traits. Our association results and functional annotation suggest the involvement of new genes in human erythropoiesis. We also confirm that rare and low-frequency variants play a role in the architecture of complex human traits, although their phenotypic effect is generally smaller than originally anticipated.
Collapse
Affiliation(s)
- Nathalie Chami
- Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; Montreal Heart Institute, Montréal, QC H1T 1C8, Canada
| | - Ming-Huei Chen
- Population Sciences Branch, National Heart, Lung, and Blood Institute, The Framingham Heart Study, Framingham, MA 01702, USA
| | - Andrew J Slater
- Genetics Target Sciences, GlaxoSmithKline, Research Triangle Park, NC 27709, USA; OmicSoft Corporation, Cary, NC 27513, USA
| | - John D Eicher
- Population Sciences Branch, National Heart, Lung, and Blood Institute, The Framingham Heart Study, Framingham, MA 01702, USA
| | - Evangelos Evangelou
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK; Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina 45110, Greece
| | - Salman M Tajuddin
- Laboratory of Epidemiology and Population Sciences, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - Latisha Love-Gregory
- Department of Medicine, Center of Human Nutrition, Washington University School of Medicine, St Louis, MO 63110, USA
| | - Tim Kacprowski
- Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine, Greifswald and Ernst-Mortiz-Arndt University Greifswald, Greifswald 17475, Germany; DZHK (German Centre for Cardiovascular Research), partner site Greifswald, Greifswald QA, Germany
| | - Ursula M Schick
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA
| | - Akihiro Nomura
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA; Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Division of Cardiovascular Medicine, Kanazawa University, Graduate School of Medical Science, Kanazawa, Ishikawa 9200942, Japan
| | - Ayush Giri
- Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN 37235, USA
| | - Samuel Lessard
- Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; Montreal Heart Institute, Montréal, QC H1T 1C8, Canada
| | - Jennifer A Brody
- Department of Medicine, University of Washington, Seattle, WA 98101, USA
| | - Claudia Schurmann
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA; The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA
| | - Nathan Pankratz
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55454, USA
| | - Lisa R Yanek
- Department of Medicine/Division of General Internal Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA
| | - Ani Manichaikul
- Center for Public Health Genomics, University of Virginia, Charlottesville, VA 22908, USA
| | - Raha Pazoki
- Department of Epidemiology, Erasmus, MC Rotterdam 3000, the Netherlands
| | - Evelin Mihailov
- Estonian Genome Center, University of Tartu, Tartu 51010, Estonia
| | - W David Hill
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8 9JZ, UK; Department of Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK
| | - Laura M Raffield
- Department of Genetics, University of North Carolina, Chapel Hill, NC 27514, USA
| | - Amber Burt
- Division of Medical Genetics, Department of Medicine, University of Washington, Seattle, WA 98195, USA
| | - Traci M Bartz
- Department of Biostatistics, University of Washington, Seattle, WA 98195, USA
| | - Diane M Becker
- Department of Medicine/Division of General Internal Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD 21205, USA
| | - Lewis C Becker
- Department of Medicine/Divisions of Cardiology and General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Eric Boerwinkle
- Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Jette Bork-Jensen
- The Novo Nordisk Foundation, Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark
| | - Erwin P Bottinger
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA
| | - Michelle L O'Donoghue
- TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115, USA
| | - David R Crosslin
- Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA 98195, USA
| | - Simon de Denus
- Montreal Heart Institute, Montréal, QC H1T 1C8, Canada; Faculty of Pharmacy, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Marie-Pierre Dubé
- Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; Montreal Heart Institute, Montréal, QC H1T 1C8, Canada
| | - Paul Elliott
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK
| | - Gunnar Engström
- Department of Clinical Sciences, Malmö, Lund University, Malmö 221 00, Sweden; Skåne University Hospital, Malmö 222 41, Sweden
| | - Michele K Evans
- Laboratory of Epidemiology and Population Sciences, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - James S Floyd
- Department of Medicine, University of Washington, Seattle, WA 98101, USA
| | - Myriam Fornage
- Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | - He Gao
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK
| | - Andreas Greinacher
- Institute for Immunology and Transfusion Medicine, University Medicine Greifswald, Greifswald 17475, Germany
| | - Vilmundur Gudnason
- Icelandic Heart Association, 201 Kopavogur, Iceland; Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
| | - Torben Hansen
- The Novo Nordisk Foundation, Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark
| | - Tamara B Harris
- Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Intramural Research Program, NIH, Bethesda, MD 20892, USA
| | - Caroline Hayward
- MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK
| | - Jussi Hernesniemi
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland; Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014, Finland; University of Tampere, School of Medicine, Tampere 33014, Finland
| | - Heather M Highland
- Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX 77030, USA; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
| | - Joel N Hirschhorn
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA; Department of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA
| | - Albert Hofman
- Department of Epidemiology, Erasmus, MC Rotterdam 3000, the Netherlands; Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA 02115, USA
| | - Marguerite R Irvin
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35233, USA
| | - Mika Kähönen
- Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland; Department of Clinical Physiology, University of Tampere School of Medicine, Tampere 33014, Finland
| | - Ethan Lange
- Departments of Genetics and Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
| | - Lenore J Launer
- Laboratory of Epidemiology, Demography, and Biometry, National Institute on Aging, Intramural Research Program, NIH, Bethesda, MD 20892, USA
| | - Terho Lehtimäki
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland; Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014, Finland
| | - Jin Li
- Department of Medicine, Division of Cardiovascular Medicine, Stanford University, School of Medicine, Palo Alto, CA 94305, USA
| | - David C M Liewald
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8 9JZ, UK; Department of Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK
| | - Allan Linneberg
- Research Centre for Prevention and Health, The Capital Region of Denmark, Copenhagen 2600, Denmark; Department of Clinical Experimental Research, Rigshospitalet, Glostrup 2100, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2200, Denmark
| | - Yongmei Liu
- Center for Human Genetics, Division of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
| | - Yingchang Lu
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA; The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA
| | - Leo-Pekka Lyytikäinen
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland; Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014, Finland
| | - Reedik Mägi
- Estonian Genome Center, University of Tartu, Tartu 51010, Estonia
| | - Rasika A Mathias
- Department of Medicine, Divisions of Allergy and Clinical Immunology and General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Olle Melander
- Department of Clinical Sciences, Malmö, Lund University, Malmö 221 00, Sweden; Skåne University Hospital, Malmö 222 41, Sweden
| | - Andres Metspalu
- Estonian Genome Center, University of Tartu, Tartu 51010, Estonia
| | - Nina Mononen
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland; Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014, Finland
| | - Mike A Nalls
- Laboratory of Neurogenetics, National Institute on Aging, NIH, Bethesda, MD 20892, USA
| | - Deborah A Nickerson
- Department of Genome Sciences, University of Washington, Seattle, WA 98105, USA
| | - Kjell Nikus
- University of Tampere, School of Medicine, Tampere 33014, Finland; Department of Cardiology, Heart Center, Tampere University Hospital, Tampere 33521, Finland
| | - Chris J O'Donnell
- Population Sciences Branch, National Heart, Lung, and Blood Institute, The Framingham Heart Study, Framingham, MA 01702, USA; Cardiology Section and Center for Population Genomics, Boston Veteran's Administration (VA) Healthcare, Boston, MA 02118, USA
| | - Marju Orho-Melander
- Department of Clinical Sciences, Malmö, Lund University, Malmö 221 00, Sweden; Skåne University Hospital, Malmö 222 41, Sweden
| | - Oluf Pedersen
- The Novo Nordisk Foundation, Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark
| | - Astrid Petersmann
- Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald 17475, Germany
| | - Linda Polfus
- Human Genetics Center, School of Public Health, University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | - Bruce M Psaty
- Cardiovascular Health Research Unit, Departments of Medicine Epidemiology and Health Services, University of Washington, Seattle, WA 98101, USA; Group Health Research Institute, Group Health Cooperative, Seattle, WA 98101, USA
| | - Olli T Raitakari
- Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku 20521, Finland; Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku 20520, Finland
| | - Emma Raitoharju
- Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland; Department of Clinical Chemistry, University of Tampere School of Medicine, Tampere 33014, Finland
| | - Melissa Richard
- Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | - Kenneth M Rice
- Department of Biostatistics, University of Washington, Seattle, WA 98195, USA
| | - Fernando Rivadeneira
- Department of Epidemiology, Erasmus, MC Rotterdam 3000, the Netherlands; Department of Internal Medicine, Erasmus MC, Rotterdam 3000, the Netherlands; Netherlands Consortium for Healthy Ageing (NCHA), Rotterdam 3015, the Netherlands
| | - Jerome I Rotter
- Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Torrance, CA 90502, USA; Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
| | - Frank Schmidt
- Department of Functional Genomics, Interfaculty Institute for Genetics and Functional Genomics, University Medicine, Greifswald and Ernst-Mortiz-Arndt University Greifswald, Greifswald 17475, Germany
| | - Albert Vernon Smith
- Icelandic Heart Association, 201 Kopavogur, Iceland; Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
| | - John M Starr
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8 9JZ, UK; Alzheimer Scotland Research Centre, Edinburgh EH8 9JZ, UK
| | - Kent D Taylor
- Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute, Torrance, CA 90502, USA; Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, CA 90502, USA
| | - Alexander Teumer
- Institute for Community Medicine, University Medicine Greifswald, Greifswald 17475, Germany
| | - Betina H Thuesen
- Research Centre for Prevention and Health, The Capital Region of Denmark, Copenhagen 2600, Denmark
| | - Eric S Torstenson
- Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN 37235, USA
| | - Russell P Tracy
- Departments of Pathology and Laboratory Medicine and Biochemistry, University of Vermont College of Medicine, Colchester, VT 05446, USA
| | - Ioanna Tzoulaki
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK; Department of Hygiene and Epidemiology, University of Ioannina Medical School, Ioannina 45110, Greece
| | - Neil A Zakai
- Departments of Medicine and Pathology, University of Vermont College of Medicine, Burlington, VT 05405, USA
| | - Caterina Vacchi-Suzzi
- Department of Family Population and Preventive Medicine, Stony Brook University, Stony Brook, NY 11794, USA
| | | | | | - Mary Cushman
- Departments of Medicine and Pathology, University of Vermont College of Medicine, Burlington, VT 05405, USA
| | - Ian J Deary
- Centre for Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, Edinburgh EH8 9JZ, UK; Department of Psychology, University of Edinburgh, Edinburgh EH8 9JZ, UK
| | - Digna R Velez Edwards
- Vanderbilt Epidemiology Center, Department of Obstetrics & Gynecology, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN 37203, USA
| | - Anne-Claire Vergnaud
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London W2 1PG, UK
| | - Lars Wallentin
- Department of Medical Sciences, Cardiology and Uppsala Clinical Research Center, Uppsala University, Uppsala 751 85, Sweden
| | - Dawn M Waterworth
- Genetics Target Sciences, GlaxoSmithKline, King of Prussia, PA 19406, USA
| | - Harvey D White
- Green Lane Cardiovascular Service, Auckland City Hospital and University of Auckland, Auckland 1142, New Zealand
| | - James G Wilson
- Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA
| | - Alan B Zonderman
- Laboratory of Epidemiology and Population Sciences, National Institute on Aging, NIH, Baltimore, MD 21224, USA
| | - Sekar Kathiresan
- Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA 02114, USA; Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA; Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
| | - Niels Grarup
- The Novo Nordisk Foundation, Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen 2100, Denmark
| | - Tõnu Esko
- Program in Medical and Population Genetics, Broad Institute, Cambridge, MA 02142, USA; Estonian Genome Center, University of Tartu, Tartu 51010, Estonia
| | - Ruth J F Loos
- The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA; The Genetics of Obesity and Related Metabolic Traits Program, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA; The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10069, USA
| | - Leslie A Lange
- Department of Genetics, University of North Carolina, Chapel Hill, NC 27514, USA
| | - Nauder Faraday
- Department of Anesthesiology & Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Nada A Abumrad
- Department of Medicine, Center of Human Nutrition, Washington University School of Medicine, St Louis, MO 63110, USA
| | - Todd L Edwards
- Division of Epidemiology, Department of Medicine, Institute for Medicine and Public Health, Vanderbilt Genetics Institute, Vanderbilt University, Nashville, TN 37235, USA
| | - Santhi K Ganesh
- Departments of Internal Medicine and Human Genetics, University of Michigan, Ann Arbor, MI 48108, USA
| | - Paul L Auer
- Zilber School of Public Health, University of Wisconsin-Milwaukee, Milwaukee, WI 53205, USA
| | - Andrew D Johnson
- Population Sciences Branch, National Heart, Lung, and Blood Institute, The Framingham Heart Study, Framingham, MA 01702, USA
| | - Alexander P Reiner
- Department of Epidemiology, University of Washington, Seattle, WA 98195, USA; Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
| | - Guillaume Lettre
- Department of Medicine, Université de Montréal, Montréal, QC H3T 1J4, Canada; Montreal Heart Institute, Montréal, QC H1T 1C8, Canada.
| |
Collapse
|
42
|
Bonecchi R, Graham GJ. Atypical Chemokine Receptors and Their Roles in the Resolution of the Inflammatory Response. Front Immunol 2016; 7:224. [PMID: 27375622 PMCID: PMC4901034 DOI: 10.3389/fimmu.2016.00224] [Citation(s) in RCA: 123] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2016] [Accepted: 05/25/2016] [Indexed: 11/13/2022] Open
Abstract
Chemokines and their receptors are key mediators of the inflammatory process regulating leukocyte extravasation and directional migration into inflamed and infected tissues. The control of chemokine availability within inflamed tissues is necessary to attain a resolving environment and when this fails chronic inflammation ensues. Accordingly, vertebrates have adopted a number of mechanisms for removing chemokines from inflamed sites to help precipitate resolution. Over the past 15 years, it has become apparent that essential players in this process are the members of the atypical chemokine receptor (ACKR) family. Broadly speaking, this family is expressed on stromal cell types and scavenges chemokines to either limit their spatial availability or to remove them from in vivo sites. Here, we provide a brief review of these ACKRs and discuss their involvement in the resolution of inflammatory responses and the therapeutic implications of our current knowledge.
Collapse
Affiliation(s)
- Raffaella Bonecchi
- Humanitas Clinical and Research Center, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Rozzano, Italy
| | - Gerard J Graham
- Chemokine Research Group, Institute of Infection, Immunity and Inflammation, University of Glasgow , Glasgow , UK
| |
Collapse
|
43
|
Chisale MR, Kumwenda P, Ngwira M, M'baya B, Chosamata BI, Mwapasa V. A pilot study to determine the normal haematological indices for young Malawian adults in Blantyre, Malawi. Malawi Med J 2016; 27:96-100. [PMID: 26715954 DOI: 10.4314/mmj.v27i3.5] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
BACKGROUND Reference ranges for haematological and other laboratory tests in most African countries are based on populations in Europe and America and, because of environmental and genetic factors, these may not accurately reflect the normal reference ranges in African populations. AIM To determine the distribution of haematological parameters in healthy individuals residing in Blantyre, Malawi. We also examined the effect of sociodemographic and nutritional factors on the haematological variables. METHODS We conducted a proof-of-concept cross-sectional study, involving 105 healthy blood donors at Malawi Blood Transfusion Service in Blantyre. Eligible participants were HIV-negative males and females, aged 19 to 35 years, who did not have any evidence of acute or chronic illness, or blood-borne infection. We performed the haematological tests at the Malawi-Liverpool Wellcome Trust laboratory in Blantyre, and the screening tests at Malawi Blood Transfusion Service laboratories. RESULTS Out of 170 consenting healthy volunteers, haematological results were available for 105 participants. The proportions of results which were below the lower limit of the manufacturer's reference ranges were 35.2% (37/105) for haemoglobin, 15.2% (16/105) for neutrophils, 23.8% (25/105) for eosinophils, and 88.6 % (93/105) for basophils. The proportions of results that were above the upper limit of the manufacturer's reference ranges were 9.5% (10/105) for platelets and 12.4% (13/105) for monocytes. We also observed that the mean leucocyte and basophil counts were significantly higher in males than females (p = 0.042 and p = 0.015, respectively). There were no statistically significant differences in haematological results observed among different ethnic, age, and body mass index groups. CONCLUSIONS Over half of otherwise healthy study participants had at least one abnormal haematological result, using previously established foreign standards. More detailed studies are needed to establish locally relevant normal ranges for different age groups and other demographic characteristics of the Malawian population. This will lead to accurate interpretation of laboratory results.
Collapse
Affiliation(s)
- M R Chisale
- Laboratory Section, Mzuzu Central Hospital, Mzuzu, Malawi
| | - P Kumwenda
- Department of Biomedical Sciences, Mzuzu University, Mzuzu, Malawi
| | - M Ngwira
- Department of Biomedical Sciences, Mzuzu University, Mzuzu, Malawi
| | - B M'baya
- Malawi Blood Transfusion Service, Blantyre, Malawi
| | - B I Chosamata
- Department of Pathology and Laboratory Sciences, College of Medicine, University of Malawi, Blantyre Malawi
| | - V Mwapasa
- Department of Public Health, College of Medicine, University of Malawi, Blantyre, Malawi
| |
Collapse
|
44
|
Unruh D, Srinivasan R, Benson T, Haigh S, Coyle D, Batra N, Keil R, Sturm R, Blanco V, Palascak M, Franco RS, Tong W, Chatterjee T, Hui DY, Davidson WS, Aronow BJ, Kalfa T, Manka D, Peairs A, Blomkalns A, Fulton DJ, Brittain JE, Weintraub NL, Bogdanov VY. Red Blood Cell Dysfunction Induced by High-Fat Diet: Potential Implications for Obesity-Related Atherosclerosis. Circulation 2015; 132:1898-908. [PMID: 26467254 PMCID: PMC4772773 DOI: 10.1161/circulationaha.115.017313] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2015] [Accepted: 08/28/2015] [Indexed: 12/31/2022]
Abstract
BACKGROUND High-fat diet (HFD) promotes endothelial dysfunction and proinflammatory monocyte activation, which contribute to atherosclerosis in obesity. We investigated whether HFD also induces the dysfunction of red blood cells (RBCs), which serve as a reservoir for chemokines via binding to Duffy antigen receptor for chemokines (DARC). METHODS AND RESULTS A 60% HFD for 12 weeks, which produced only minor changes in lipid profile in C57/BL6 mice, markedly augmented the levels of monocyte chemoattractant protein-1 bound to RBCs, which in turn stimulated macrophage migration through an endothelial monolayer. Levels of RBC-bound KC were also increased by HFD. These effects of HFD were abolished in DARC(-/-) mice. In RBCs from HFD-fed wild-type and DARC(-/-) mice, levels of membrane cholesterol and phosphatidylserine externalization were increased, fostering RBC-macrophage inflammatory interactions and promoting macrophage phagocytosis in vitro. When labeled ex vivo and injected into wild-type mice, RBCs from HFD-fed mice exhibited ≈3-fold increase in splenic uptake. Finally, RBCs from HFD-fed mice induced increased macrophage adhesion to the endothelium when they were incubated with isolated aortic segments, indicating endothelial activation. CONCLUSIONS RBC dysfunction, analogous to endothelial dysfunction, occurs early during diet-induced obesity and may serve as a mediator of atherosclerosis. These findings may have implications for the pathogenesis of atherosclerosis in obesity, a worldwide epidemic.
Collapse
Affiliation(s)
- Dusten Unruh
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Ramprasad Srinivasan
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Tyler Benson
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Stephen Haigh
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Danielle Coyle
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Neil Batra
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Ryan Keil
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Robert Sturm
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Victor Blanco
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Mary Palascak
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Robert S Franco
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Wilson Tong
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Tapan Chatterjee
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - David Y Hui
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - W Sean Davidson
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Bruce J Aronow
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Theodosia Kalfa
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - David Manka
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Abigail Peairs
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Andra Blomkalns
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - David J Fulton
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Julia E Brittain
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Neal L Weintraub
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.)
| | - Vladimir Y Bogdanov
- From Hematology/Oncology, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.U., R.S., R.K., R.S., V.B., M.P., R.S.F., V.Y.B.); Vascular Biology Center, Georgia Regents University, Augusta, GA (T.B., S.H., T.C., D.J.F., N.L.W.); Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, University of Cincinnati, OH (D.C., N.B., W.T., D.M.); Department of Nutritional Sciences, College of Allied Health Sciences, University of Cincinnati, OH (D.C., A.P.); Department of Pathology, College of Medicine, University of Cincinnati, OH (D.Y.H., W.S.D.); Biomedical Informatics and Developmental Biology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (B.J.A.); Experimental Hematology / Department of Pediatrics, College of Medicine, University of Cincinnati and Cincinnati Children's Hospital and Medical Center, OH (T.K.); Hemoshear LLC, Charlottesville, VA (D.M.); and Department of Emergency Medicine, University of Texas Southwestern Medical Center, Dallas (A.B.).
| |
Collapse
|
45
|
Affiliation(s)
- Daniel I Simon
- From Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH (D.I.S.); and Department of Medicine, Medical College of Wisconsin and Blood Research Institute, Blood Center of Wisconsin, Milwaukee (R.L.S.).
| | - Roy L Silverstein
- From Harrington Heart & Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH (D.I.S.); and Department of Medicine, Medical College of Wisconsin and Blood Research Institute, Blood Center of Wisconsin, Milwaukee (R.L.S.)
| |
Collapse
|
46
|
Yu KD, Wang X, Yang C, Zeng XH, Shao ZM. Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse. Oncotarget 2015; 6:26519-27. [PMID: 26314842 PMCID: PMC4694919 DOI: 10.18632/oncotarget.4470] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2015] [Accepted: 06/25/2015] [Indexed: 12/17/2022] Open
Abstract
PURPOSE Chemokines may play vital roles in breast cancer progression and metastasis. The primary members of chemokine decoy receptors (CDR), DARC and D6, are expressed in breast tumors and lymphatic/hematogenous vessels. CDRs sequestrate the pro-malignant chemokines. We hypothesized that breast cancer patients carrying different levels of CDR expression in tumor and/or in host might have differing clinical outcomes. METHODS This prospective observational study measured both expression and germline genotype of DARC and D6 in 463 primary breast cancer patients enrolled between 2004 and 2006. The endpoint was breast cancer relapse-free survival (RFS). RESULTS There was a significant association between the co-expression of CDR (immunohistochemical expression of both DARC and D6) with RFS (hazard ratio [HR] of 0.32, 95% confidence interval [CI] 0.19 to 0.54). Furthermore, the co-genotype of two non-synonymous polymorphisms (with two major alleles of DARC-rs12075 and D6-rs2228468 versus the others) significantly related to relapse. Mechanistically, the variant-alleles of these two polymorphisms significantly decreased by 20-30% of CCL2/CCL5 (CDR ligands) levels relative to their major counterparts. Multivariate analysis highlighted that the co-expression and co-genotype of CDR were independent predictors of RFS, with HR of 0.46 (95% CI 0.27 to 0.80) and 0.56 (95% CI 0.37 to 0.85), respectively. The addition of host CDR genetic information to tumor-based factors (including co-expression of CDR) improved the relapse prediction ability (P = 0.02 of AUC comparison). CONCLUSION The host genotype and tumor phenotype of CDR integrally affect breast cancer relapse. Host-related factors should be considered for individualized prediction of prognosis.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Breast Neoplasms/mortality
- Breast Neoplasms/pathology
- Breast Neoplasms/therapy
- Cell Line, Tumor
- Chemokine CCL2/metabolism
- Chemokine CCL5/metabolism
- Chi-Square Distribution
- Disease-Free Survival
- Duffy Blood-Group System/genetics
- Female
- Gene Frequency
- Genetic Predisposition to Disease
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Middle Aged
- Multivariate Analysis
- Neoplasm Recurrence, Local
- Phenotype
- Polymorphism, Single Nucleotide
- Proportional Hazards Models
- Prospective Studies
- Receptors, CCR10/genetics
- Receptors, Cell Surface/genetics
- Receptors, Chemokine/genetics
- Receptors, Chemokine/metabolism
- Risk Assessment
- Risk Factors
- Time Factors
- Transfection
- Treatment Outcome
- Chemokine Receptor D6
Collapse
Affiliation(s)
- Ke-Da Yu
- Department of Breast Surgery, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, P.R. China
| | - Xin Wang
- Department of Anesthesiology, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, P.R. China
| | - Chen Yang
- Department of Medical Oncology, Ruijin Hospital, Shanghai JiaoTong University, Shanghai, P.R. China
| | - Xiao-Hua Zeng
- Department of Breast Surgery, Chongqing Cancer Institute/Hospital, Chongqing, P.R. China
| | - Zhi-Ming Shao
- Department of Breast Surgery, Shanghai Cancer Center and Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, P.R. China
| |
Collapse
|
47
|
Zhang WB, Shao WB, Li FZ, Gong JX, Yang Z. Asymmetric Total Synthesis of (−)-Maoecrystal V. Chem Asian J 2015; 10:1874-80. [DOI: 10.1002/asia.201500564] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Indexed: 01/05/2023]
Affiliation(s)
- Wei-bin Zhang
- Laboratory of Chemical Genomics; School of Chemical Biology and Biotechnology; Peking University Shenzhen Graduate School; Shenzhen 518055 China
| | - Wen-bin Shao
- Laboratory of Chemical Genomics; School of Chemical Biology and Biotechnology; Peking University Shenzhen Graduate School; Shenzhen 518055 China
| | - Fu-zhuo Li
- Laboratory of Chemical Genomics; School of Chemical Biology and Biotechnology; Peking University Shenzhen Graduate School; Shenzhen 518055 China
| | - Jian-xian Gong
- Laboratory of Chemical Genomics; School of Chemical Biology and Biotechnology; Peking University Shenzhen Graduate School; Shenzhen 518055 China
| | - Zhen Yang
- Laboratory of Chemical Genomics; School of Chemical Biology and Biotechnology; Peking University Shenzhen Graduate School; Shenzhen 518055 China
- Key Laboratory of Bioorganic Chemistry and Molecular Engineering of Ministry of Education and; Beijing National Laboratory for Molecular Science (BNLMS); Peking-Tsinghua Center for Life Sciences; Peking University; Beijing 100871 China
- Key Laboratory of Marine Drugs; Chinese Ministry of Education; School of Medicine and Pharmacy; Ocean University of China; 5 Yushan Road Qingdao China
| |
Collapse
|
48
|
Li ZL, Ye SB, OuYang LY, Zhang H, Chen YS, He J, Chen QY, Qian CN, Zhang XS, Cui J, Zeng YX, Li J. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology 2015; 4:e1044712. [PMID: 26451317 DOI: 10.1080/2162402x.2015.1044712] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 04/08/2015] [Accepted: 04/21/2015] [Indexed: 01/02/2023] Open
Abstract
The expansion of myeloid-derived suppressor cells (MDSCs) is a common feature of cancer, but its biological roles and molecular mechanism remain unclear. Here, we investigated a molecular link between MDSC expansion and tumor cell metastasis in nasopharyngeal carcinoma (NPC). We demonstrated that MDSCs expanded and were positively correlated with the elevated tumor COX-2 expression and serum IL-6 levels in NPC patients. Importantly, COX-2 and MDSCs were poor predictors of patient disease-free survival (DFS). Knocking down tumor COX-2 expression hampered functional TW03-mediated-MDSC cell (T-MDSC) induction with IL-6 blocking. We identified that T-MDSCs promoted NPC cell migration and invasion by triggering the epithelial-mesenchymal transition (EMT) on cell-to-cell contact, and T-MDSCs enhanced tumor experimental lung metastasis in vivo. Interestingly, the contact between T-MDSCs and NPC cells enhanced tumor COX-2 expression, which subsequently activated the β-catenin/TCF4 pathway, resulting in EMT of the cancer cells. Blocking transforming growth factor β (TGFβ) or inducible nitric oxide synthase (iNOS) significantly abolished the T-MDSC-induced upregulation of COX-2 and EMT scores in NPC cells, whereas the administration of TGFβ or L-arginine supplements upregulated COX-2 expression and EMT scores in NPC cells. These findings reveal that COX-2 is a key factor mediating the interaction between MDSCs and tumor cells, suggesting that the inhibition of COX-2 or MDSCs has the potential to suppress NPC metastasis.
Collapse
Affiliation(s)
- Ze-Lei Li
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Shu-Biao Ye
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Li-Yin OuYang
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Han Zhang
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Yu-Shan Chen
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Radiotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Jia He
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Qiu-Yan Chen
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Nasopharyngeal Carcinoma; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Chao-Nan Qian
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Nasopharyngeal Carcinoma; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Xiao-Shi Zhang
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Jun Cui
- Key Laboratory of Gene Engineering of the Ministry of Education; State Key Laboratory of Biocontrol; College of Life Sciences; Sun Yat-sen University ; Guangzhou, China
| | - Yi-Xin Zeng
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| | - Jiang Li
- State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China ; Department of Biotherapy; Sun Yat-Sen University Cancer Center (SYSUCC) ; Guangzhou, China
| |
Collapse
|
49
|
Wan W, Liu Q, Lionakis MS, Marino APMP, Anderson SA, Swamydas M, Murphy PM. Atypical chemokine receptor 1 deficiency reduces atherogenesis in ApoE-knockout mice. Cardiovasc Res 2015; 106:478-87. [PMID: 25858253 PMCID: PMC4447808 DOI: 10.1093/cvr/cvv124] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Revised: 03/18/2015] [Accepted: 03/20/2015] [Indexed: 12/14/2022] Open
Abstract
AIMS Atypical chemokine receptor 1 (Ackr1; previously known as the Duffy antigen receptor for chemokines or Darc) is thought to regulate acute inflammatory responses in part by scavenging inflammatory CC and CXC chemokines; however, evidence for a role in chronic inflammation has been lacking. Here we investigated the role of Ackr1 in chronic inflammation, in particular in the setting of atherogenesis, using the apolipoprotein E-deficient (ApoE(-/-)) mouse model. METHODS AND RESULTS Ackr1(-/-)ApoE(-/-) and Ackr1(+/+)ApoE(-/-) littermates were obtained by crossing ApoE(-/-) mice and Ackr1(-/-) mice on a C57BL/6J background. Ackr1 (+/+)ApoE(-/-)mice fed a Western diet up-regulated Ackr1 expression in the aorta and had markedly increased atherosclerotic lesion size compared with Ackr1(-/-)ApoE(-/-) mice. This difference was observed in both the whole aorta and the aortic root in both early and late stages of the model. Ackr1 deficiency did not affect serum cholesterol levels or macrophage, collagen or smooth muscle cell content in atherosclerotic plaques, but significantly reduced the expression of Ccl2 and Cxcl1 in the whole aorta of ApoE(-/-) mice. In addition, Ackr1 deficiency resulted in a modest decrease in T cell subset frequency and inflammatory mononuclear phagocyte content in aorta and blood in the model. CONCLUSIONS Ackr1 deficiency appears to be protective in the ApoE knockout model of atherogenesis, but it is associated with only modest changes in cytokine and chemokine expression as well as T-cell subset frequency and inflammatory macrophage content.
Collapse
Affiliation(s)
- Wuzhou Wan
- Molecular Signaling Section, Laboratory of Molecular Immunology (LMI), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Qian Liu
- Molecular Signaling Section, Laboratory of Molecular Immunology (LMI), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Michail S Lionakis
- Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
| | - Ana Paula M P Marino
- Molecular Signaling Section, Laboratory of Molecular Immunology (LMI), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| | - Stasia A Anderson
- National Heart, Lung and Blood Institute (NHLBI) Animal MRI Core, NIH, Bethesda, MD, USA
| | - Muthulekha Swamydas
- Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, NIAID, NIH, Bethesda, MD, USA
| | - Philip M Murphy
- Molecular Signaling Section, Laboratory of Molecular Immunology (LMI), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA
| |
Collapse
|
50
|
Hernández-Aguilera A, Sepúlveda J, Rodríguez-Gallego E, Guirro M, García-Heredia A, Cabré N, Luciano-Mateo F, Fort-Gallifa I, Martín-Paredero V, Joven J, Camps J. Immunohistochemical analysis of paraoxonases and chemokines in arteries of patients with peripheral artery disease. Int J Mol Sci 2015; 16:11323-38. [PMID: 25993297 PMCID: PMC4463702 DOI: 10.3390/ijms160511323] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2015] [Revised: 04/15/2015] [Accepted: 04/22/2015] [Indexed: 12/31/2022] Open
Abstract
Oxidative damage to lipids and lipoproteins is implicated in the development of atherosclerotic vascular diseases, including peripheral artery disease (PAD). The paraoxonases (PON) are a group of antioxidant enzymes, termed PON1, PON2, and PON3 that protect lipoproteins and cells from peroxidation and, as such, may be involved in protection against the atherosclerosis process. PON1 inhibits the production of chemokine (C–C motif) ligand 2 (CCL2) in endothelial cells incubated with oxidized lipoproteins. PON1 and CCL2 are ubiquitously distributed in tissues, and this suggests a joint localization and combined systemic effect. The aim of the present study has been to analyze the quantitative immunohistochemical localization of PON1, PON3, CCL2 and CCL2 receptors in a series of patients with severe PAD. Portions of femoral and/or popliteal arteries from 66 patients with PAD were obtained during surgical procedures for infra-inguinal limb revascularization. We used eight normal arteries from donors as controls. PON1 and PON3, CCL2 and the chemokine-binding protein 2, and Duffy antigen/chemokine receptor, were increased in PAD patients. There were no significant changes in C–C chemokine receptor type 2. Our findings suggest that paraoxonases and chemokines play an important role in the development and progression of atherosclerosis in peripheral artery disease.
Collapse
Affiliation(s)
- Anna Hernández-Aguilera
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Julio Sepúlveda
- Service of Angiology, Vascular Surgery and Endosurgery, Hospital Universitari Joan XXIII, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Tarragona, Catalonia 43005, Spain.
| | - Esther Rodríguez-Gallego
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Maria Guirro
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Anabel García-Heredia
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Noemí Cabré
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Fedra Luciano-Mateo
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Isabel Fort-Gallifa
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Vicente Martín-Paredero
- Service of Angiology, Vascular Surgery and Endosurgery, Hospital Universitari Joan XXIII, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Tarragona, Catalonia 43005, Spain.
| | - Jorge Joven
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| | - Jordi Camps
- Biomedical Research Unit, Hospital Universitari de Sant Joan, Institut d'Investigacio Sanitaria Pere Virgili, Universitat Rovira i Virgili, Reus, Catalonia 43201, Spain.
| |
Collapse
|